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Abstract
Asthma is characterized by airway hyperresponsiveness (AHR) and inflammation. Management of asthma
involves controlling airway inflammation with inhaled corticosteroids, and using bronchodilators such as β-2
agonists that inhibit airway smooth muscle (ASM) shortening and prevents or reverses airway narrowing.
Despite β-2 agonists’ ability to mitigate asthma exacerbations, they have limitations, especially concerning
efficacy and safety. Studies have shown that β-2 agonist use can result in adverse patient outcomes, β-2
adrenergic receptor tachyphylaxis, deterioration of asthma control, and death. New therapeutics are needed to
overcome these limitations. Rho kinase (ROCK) inhibitors have generated excitement as potential
bronchodilators. Since ROCK activation is necessary to maintain ASM tone by inhibiting MLC phosphatase,
ROCK inhibitors allow the constitutively active MLC phosphatase to de-phosphorylate MLC and promote
relaxation of ASM. ROCK inhibitors blunt ASM contraction and induce bronchodilation in vitro, ex vivo, and
in vivo. Unfortunately, ROCK is ubiquitously expressed and adverse effects such as vasodilation preclude any
clinical trials. We present an alternate strategy to induce bronchodilation in human airways by inhibiting the
p110δ isoform of phosphoinositide 3-kinase (PI3Kδ) that is not ubiquitously expressed. In primary human
ASM cells (HASMCs), we demonstrate that PI3Kδ modulates ROCK activation, and that inhibition of PI3Kδ
using a FDA approved drug Cal101 (Idelalisib) attenuates ROCK activation. Cal101 induces relaxation of
cultured HASMCs by inhibiting PI3Kδ-mediated activation of ROCK. Using human precision-cut lung slices,
we also demonstrate that Cal101 induces bronchodilation of human small airways as effectively as formoterol,
an industry standard β-2 agonist. In our model of β-2 agonist tachyphylaxis, the effectiveness of β-2 agonists
was significantly attenuated while the effectiveness of Cal101 was not. Thus, our results suggest that PI3Kδ
inhibitors represent a novel class of bronchodilators. Furthermore, we demonstrate that Gα12 mediates
agonist-induced activation of PI3K and ROCK. These results unveil a novel pathway regulating HASMC
signaling that is necessary to elicit shortening. Importantly, our work has uncovered several new targets for
bronchodilation and offers new avenues for the treatment of asthma.
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ABSTRACT 
 
TARGETING CALCIUM SENSITIZATION MECHANISMS FOR NOVEL BRONCHODILATOR 
THERAPY IN ASTHMA 
 
Edwin J. Yoo 
Dr. Reynold A. Panettieri, Jr. 
 
Asthma is characterized by airway hyperresponsiveness (AHR) and 
inflammation.  Management of asthma involves controlling airway inflammation with 
inhaled corticosteroids, and using bronchodilators such as β-2 agonists that inhibit 
airway smooth muscle (ASM) shortening and prevents or reverses airway narrowing.  
Despite β-2 agonists’ ability to mitigate asthma exacerbations, they have limitations, 
especially concerning efficacy and safety.  Studies have shown that β-2 agonist use can 
result in adverse patient outcomes, β-2 adrenergic receptor tachyphylaxis, deterioration 
of asthma control, and death.  New therapeutics are needed to overcome these 
limitations.   Rho kinase (ROCK) inhibitors have generated excitement as potential 
bronchodilators.  Since ROCK activation is necessary to maintain ASM tone by inhibiting 
MLC phosphatase, ROCK inhibitors allow the constitutively active MLC phosphatase to 
de-phosphorylate MLC and promote relaxation of ASM.  ROCK inhibitors blunt ASM 
contraction and induce bronchodilation in vitro, ex vivo, and in vivo.  Unfortunately, 
ROCK is ubiquitously expressed and adverse effects such as vasodilation preclude any 
clinical trials.  We present an alternate strategy to induce bronchodilation in human 
airways by inhibiting the p110δ isoform of phosphoinositide 3-kinase (PI3Kδ) that is not 
ubiquitously expressed.  In primary human ASM cells (HASMCs), we demonstrate that 
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PI3Kδ modulates ROCK activation, and that inhibition of PI3Kδ using a FDA approved 
drug Cal101 (Idelalisib) attenuates ROCK activation.  Cal101 induces relaxation of 
cultured HASMCs by inhibiting PI3Kδ-mediated activation of ROCK.  Using human 
precision-cut lung slices, we also demonstrate that Cal101 induces bronchodilation of 
human small airways as effectively as formoterol, an industry standard β-2 agonist. In 
our model of β-2 agonist tachyphylaxis, the effectiveness of β-2 agonists was significantly 
attenuated while the effectiveness of Cal101 was not.  Thus, our results suggest that 
PI3Kδ inhibitors represent a novel class of bronchodilators.  Furthermore, we 
demonstrate that Gα12 mediates agonist-induced activation of PI3K and ROCK.  These 
results unveil a novel pathway regulating HASMC signaling that is necessary to elicit 
shortening.  Importantly, our work has uncovered several new targets for 
bronchodilation and offers new avenues for the treatment of asthma. 
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CHAPTER 1:  Introduction and Comprehensive Literature Review  
 
 
Edwin J. Yoo 
Rutgers Institute For Translational Medicine and Science, Child Health Institute, Rutgers 
University, New Brunswick, NJ 
 
This chapter was adapted from work originally published in the American Journal of Respiratory 
Cell and Molecular Biology, December 2016	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Asthma and Airway Smooth Muscle 
	  
Asthma is characterized by airway hyperresponsiveness (AHR), inflammation, 
and reversible bronchoconstriction.  It is a major contributor to morbidity, mortality, 
and healthcare expenditures in the United States, costing approximately $50 billion 
yearly in direct healthcare costs1.  The mainstay of asthma treatment consists of 
corticosteroids to prevent inflammation and bronchodilators like β–agonists, which 
reverse and prevent bronchoconstriction by relaxing ASM.  Unfortunately, about 50% of 
asthmatics have inadequate control with current therapeutics2.  Evidence suggests that 
the regular use of β-agonists increases AHR3,4, worsens asthma control2,5, and increases 
morbidity and mortality5–7.  Truly novel bronchodilators that overcome the limitations of 
current drugs have yet to emerge.  
PI3K Activation and Function 
 
Initially discovered in studies of carcinogenesis, PI3K mediates cell functions 
including proliferation, metabolism, and motility – all of which are important to cancer 
progression8.  Other studies determined that PI3K plays a role in a myriad of diseases.   
 PI3K phosphorylates the D-3 position of the plasma membrane lipid 
phosphatidylinositol-4-5-bisphosphate [PI(4,5)P2], generating phosphatidylinositol-3-4-
5-trisphosphate [PI(3,4,5)P3]9,10.   Cytosolic signaling proteins with pleckstrin-homology 
(PH) domains accumulate at sites of PI3K activation by direct binding to PI(3,4,5)P3.  
Proteins with PH domains include protein kinases, scaffolding proteins, and guanine 
exchange factors (GEFs), all of which will become activated and initiate signaling 
cascades11–14.  Notable effectors of PI3K signaling include protein serine-threonine 
kinases Akt and phosphoinositide-dependent kinase 1 (PDK1), as shown in Figure 1.  
Binding of Akt and PDK1 to PI(3,4,5)P3 brings these proteins into proximity, inducing 
3	  
	  
phosphorylation of Akt by PDK1.  Activation of Akt by PDK1 activates mammalian target 
of rapamycin complex 1 (mTORC1) and a host of other proteins, affecting cell growth and 
proliferation15. 
 Signaling of the PI3K pathway terminates by dephosphorylation of PI(3,4,5)P3 by 
the enzyme phosphatase and tensin homolog (PTEN), the main endogenous PI3K 
inhibitor16.  PTEN is a tumor suppressor and is important in many cancers.  The PI3K 
pathway is also inactivated by Src-homology domain 2 (SH2)-containing phosphatases 
SHIP1 and SHIP2, found primarily in blood cells17. 
 PI3Ks consist of heterodimers composed of a p110 catalytic subunit and a 
regulatory subunit.  The PI3K family is divided into three classes (class I, II, and III) 
based on structural and functional characteristics, as shown in Figure 1.  Further divided 
into subclasses based on their p110 catalytic subunit, class IA PI3Ks are composed of 
p110α, p110β, and p110δ isoforms while class IB contains solely the p110γ isoform.  Class 
IA PI3Ks contain p85, p55, or p50 phosphotyrosine-binding regulatory subunits.  Class 
IB PI3Ks contain p101 or p84/p87 regulatory subunits, that allow activation by the βγ 
subunits of G-protein coupled receptors (GPCRs)18.  Class II PI3Ks consist of three 
isoforms (C2α, C2β, and C2γ) that are ubiquitously expressed19,20.  Class III PI3K 
includes only one member, vacuolar protein sorting mutant 34 (Vps34p), that regulates 
endocytosis, toll-like receptor signaling, and vesicular trafficking21. Classes II and III are 
not well studied due to the lack of highly selective pharmacological inhibitors. Class I is 
the most thoroughly studied PI3K family, and will be the focus of this review. 
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Functions of Class I PI3K 
 
Due to the limitations of selective inhibition strategies, the study of Class I PI3K 
family members remains challenging22.  Unlike the p110δ and p110γ subunits, the p110α 
and p110β subunits are required for cell proliferation and embryonic development23.  
Consequently, in vivo experiments requiring genetic knockdown of p110α and p110β 
pose obstacles.   
 The p110δ and p110γ isoforms are predominantly, but not exclusively, expressed 
in leukocytes, and play important roles in innate and adaptive immune responses24.  
Activated toll-like-receptors (TLRs) in leukocytes recruit p110δ and p110γ and initiate 
signaling25.  In T-cells, p110δ and p110γ negatively regulate TLR-induced interleukin-12 
and interferon-γ production, facilitating Th1 responses and diminishing Th2 responses26.  
p110δ knockout mice and mice expressing inactive p110δ catalytic subunit demonstrate 
impaired CD28-costimulated clonal expansion and differentiation, highlighting the 
necessity of p110δ in T-cell activation27,28.  Interestingly, patients with activated PI3K 
delta syndrome (APDS) manifest increased susceptibility to airway infections, 
bronchiectasis, and lymphoproliferation29.  p110γ deficient mice display reduced 
thymocyte survival and T-cell maturation, with a significant decrease in CD4+ cells30.  
PI3K also mediates B-cell function as p110δ knockout mice display impaired B-cell 
receptor-mediated antigen presentation31.  In neutrophils, PI3K regulates NADPH 
Oxidase and is important for reactive oxygen species generation.  Stimulation of 
numerous neutrophil receptors including GPCRs, cytokine receptors, integrin receptors, 
and Fc receptors, activates GEFs.  GEFs, such as PRex1 and Cytohesin4, mediate 
chemotaxis, vesicle trafficking, degranulation, and NADPH Oxidase activation32.  
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 PI3K serves to promote immune cell survival by modulating anti-apoptosis 
signaling.  The PI3K/AKT pathway inhibits pro-apoptotic proteins including B-cell 
lymphoma 2 (Bcl2) and associated proteins.  PI3K signaling also facilitates activation of 
pro-survival proteins including BCL-XL, MCL-1, and NF-κB33. 
 Collectively, these studies demonstrate that p110δ and p110γ are integral to the 
orchestration of both the innate and adaptive immune responses, including leukocyte 
migration, activation, B-cell and T-cell maturation, neutrophil NADPH Oxidase 
activation, and antigen response. 
 
PI3K and Asthma 
 
Atopic asthma manifests when T-cells mature into a Th2 subtype upon allergen 
exposure and release mediators that activate other immune cells such as mast cells, 
granulocytes, and B-cells.  Activated immune cells then elicit responses from structural 
cells such as ASM and airway epithelial cells, which culminate in AHR, inflammation, 
and remodeling.  PI3Ks play important roles in the responses of airway immune cells 
and structural cells that mediate these pathophysiological processes.   
 The importance of PI3K in asthma is demonstrated by in vivo experiments that 
show that PI3K inhibitors prevent pathogenesis of allergen-induced AHR and 
inflammation34,35.  IC87114, a p110δ selective inhibitor, attenuated allergic airway 
inflammation and AHR in a murine model36.  p110δ also mediates lung inflammation 
induced by Aspergillus fumigatus via a mechanism involving endoplasmic reticulum 
stress37.  Additionally, allergen-induced AHR does not develop in p110γ-deficient mice38.  
Taken together, these experiments suggest that PI3K is necessary for the development of 
asthma. 
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PI3K and Asthma:  Structural Cells 
 
Structural cells, including airway smooth muscle cells and epithelial cells, are the 
main effector cells of inflammatory mediators released during asthma.  Airway smooth 
muscle cells proliferate and shorten upon exposure to inflammatory mediators, inducing 
airway remodeling and obstruction39.  Epithelial cells recruit eosinophils by releasing 
eotaxin.  Eosinophils subsequently release major basic protein, inducing epithelial 
damage40.  PI3Ks play an important role in mediating both ASM and epithelial cell 
responses. 
 ASM, the pivotal cell type mediating AHR, is the primary target for 
bronchodilation, a major therapeutic strategy.  In asthma, ASM maintains airway tone, 
secretes inflammatory mediators, and undergoes hypertrophy and hyperplasia.  ASM 
shortening occurs upon agonist binding to a GPCR, resulting in an elevation of 
intracellular calcium, myosin light chain (MLC) phosphorylation, and actin-myosin 
cross-bridge cycling, via the canonical inositol trisphosphate and calmodulin mediated 
pathway.  In parallel, inhibition of myosin light-chain phosphatase by Rho Kinase 
(ROCK) sustains MLC phosphorylation and maintains ASM tone.  
PI3K activation is necessary for the modulation of ASM contraction and the 
accumulation of contractile proteins41,42.  Importantly, PI3K contributes to airway tone 
via its regulation of ROCK.  In human ex-vivo small airways contracted to agonist, PI3K 
inhibitors evoke bronchodilation43.  P110δ and p110γ subunits are required for the 
development of AHR in mice36,44,45.  Furthermore, cytokine-mediated induction of CD38, 
a calcium signaling protein important to the development of AHR, was impaired 
following treatment with PI3K inhibitors46.  P110γ activity was found to be elevated in 
ASM derived from subjects with asthma, and was also important for β-2 adrenergic 
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receptor resensitization47.  These studies highlight the importance of PI3K in ASM 
contraction and AHR development.   
 ASM also secretes chemokines and cytokines such as IL-6, VEGF, and CXCL-8 
that contribute to the recruitment of immune cells in asthma.  PI3K is necessary for IL-6 
secretion induced by TGFβ, a cytokine important to airway remodeling and AHR 
development48.  Under mechanical strain, ASM signals through PI3K/Akt/mTOR and 
ERK pathways, inducing HIF-1α, a transcription factor required for VEGF expression49.  
VEGF release by mechanical strain of HASM may account for the angiogenesis seen after 
repeated asthma exacerbations49.  Additionally, PI3K and MAPK pathways regulate the 
synergy of IL-17 and IL-1 beta to enhance CXCL-8 expression50.  Taken together, these 
studies highlight the importance of PI3K to ASM chemokine and cytokine secretion. 
 In addition to ASM contraction and mediator secretion, PI3K plays an important 
role in airway remodeling.  Airway remodeling refers to the structural changes that occur 
during asthma.  ASM undergoes hyperplasia and hypertrophy to increase ASM mass.  
Th2 cytokines modulate airway contraction by secreting MMP-1 from the ASM cells via 
PI3K activation51.  PI3K is also required for growth factor-induced cell migration52–55.  
Furthermore, activation of class IA PI3K is sufficient to stimulate DNA synthesis and 
growth, that promote airway remodeling56.   
ASM derived from subjects with asthma display increased proliferation, responsiveness 
to contractile agonist, and mediator release, suggesting an epigenetic alteration.  Small 
RNAs are essential to the establishment of an epigenetic signature, and profiling of small 
RNAs suggests that the PI3K pathway is enhanced in bronchial smooth muscle cells from 
patients with asthma57. 
 The airway epithelium, considered an essential modulator of inflammation, lie at 
the interface between the host and the environment.  The epithelium represents the first 
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line of defense against microorganisms, toxicants, and allergens and express many 
pattern recognition receptors (PRRs) to rapidly detect and respond to pathogen-
associated molecular patterns (PAMPs) found in microbes or to damage-associated 
molecular patterns (DAMPs) released upon tissue damage, cell death, or cellular stress.  
Activation of epithelial PRRs releases cytokines, chemokines, and antimicrobial 
peptides, that attracts and activates innate and adaptive immune cells.  Studies show 
that endothelial cell activation is a key-triggering event in the recognition of inhaled 
allergens that activates the local network of dendritic cells (DCs), that coordinate the 
subsequent immune response.  PI3K mediates epithelial responses to environmental 
stimuli.  PI3K is important during viral-induced asthma exacerbations due to it’s 
importance in virus internalization58,59.  In an allergen-induced model of asthma, PI3K 
activation is increased and PTEN activation is decreased in the airway epithelium.  PTEN 
protein expression and PTEN activity were also decreased in epithelial cells of mice 
exposed to allergen.  Immunoreactive PTEN localized in epithelial layers around the 
bronchioles of control mice; PTEN rapidly disappeared in allergen-exposed lungs of 
mice, suggesting that the PI3K/PTEN pathway modulates epithelial cell function in 
asthma60. 
 PI3K also facilitates mediator release from epithelial cells61,62.  PI3K inhibition 
prevents expression of IP-10; a mediator released during virus-induced asthma 
exacerbations63.  PI3K also modulates iNOS and NO signaling in the airway epithelium, 
promoting the development of airway inflammation63,64.  P110δ inhibition attenuates 
antigen-induced airway inflammation and hyperresponsiveness through the modulation 
VEGF-induce vascular leakage65.  PI3K inhibition also reduced the mucus hypersecretory 
phenotype and goblet cell metaplasia induced by IL-13, an important cytokine that is 
associated with asthma66. 
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PI3K and Asthma:  Immune Cells 
 
Allergen exposure induces Th2 differentiation of T-cells that in turn secrete cytokines 
that promote allergic inflammation.  Th2 cytokines stimulate B-cells to produce IgE and 
other antibodies.  These cytokines include IL-4, that stimulates the production of IgE, 
IL-5, that activates locally recruited eosinophils, and IL-13, that stimulates mucus 
secretion from bronchial submucosal glands and promotes IgE production by B cells.  As 
in other hypersensitivity reactions, IgE coats submucosal mast cells, and repeat exposure 
to the allergen triggers the mast cells to release granule contents and produce cytokines 
and other mediators, that collectively induce an asthma phenotype. 
 T-cells, in part, promote the development of asthma, secreting cytokines that are 
sufficient to induce AHR and B-cell class switching to IgE.  Class I PI3Ks play roles in T-
cell activation, differentiation, and proliferation, with p110δ and p110γ being the main 
contributors, as shown in Figure 2.  Upon activation by antigen presenting cells, naïve 
CD4+ cells will proliferate and differentiate to various T helper effector subsets, 
including the Th2 subtype.  Class I PI3Ks have important roles in T-cell functions.  T-cell 
receptor engagement by antigen activates p110δ through tyrosine kinase signaling 
cascades67.  p110γ is recruited by G-protein activation through GPCRs, that include 
chemokine receptors68.  Mice lacking both p110δ and p110γ are markedly impaired in T-
cell development, and are unable to rearrange the T-cell receptor α and β chains69.  In 
naïve CD4+ T-cells, evidence suggests that class I PI3Ks are activated upon engagement 
by antigen presenting cells70.  PI3Ks are required for the differentiation of Th effector 
subsets, with Th2 differentiation being necessary for the development of atopic asthma28. 
B-cells secrete IgE into circulation, that will then bind to high-affinity FcϵR1 receptors on 
the surface of mast cells.  PI3K negatively regulates IgE expression and IgE cell surface 
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receptor expression levels.  Blockade of PI3K signaling markedly enhanced B-cell IgE 
class-switching and increased IgE levels in vivo, despite reduced type-2 cytokine 
production71,72. 
 Mast cells, the central effector cell in allergic diseases, are present in increased 
numbers in the airways of patients with asthma.  Binding of allergen to IgE on the cell 
surface induces a signal transduction cascade that releases mediators such as histamine 
and prostaglandin D2 (PGD2).  The release of histamine and PGD2 evokes 
bronchoconstriction.  IgE-mediated mast cell degranulation is augmented by PI3K73.  
Additionally, PI3K was found to mediate VEGF release in murine models, which in turn 
promotes vascular leakage in asthma74. 
 Increased numbers of eosinophils are also present in the airways of some patients 
with asthma.  The recruitment, growth, and survival of eosinophils is promoted by 
factors released from airway epithelial cells, Th2 cells, and mast cells.  Eosinophils 
express a variety of proinflammatory cytokines, Th2 cytokines, and chemokines that can 
activate mast cells and stimulate the epithelium.  Eosinophils can also present antigen to 
T cells, and release growth factors such as TGF-β, promoting inflammation in asthma. 
Inhibition of PI3K blunts eosinophil chemotaxis, a function important in asthma75,76.  
Additionally, PI3K induces mediator release in allergic asthma, irrespective of allergen 
challenge model77.  Eosinophils derived from subjects with atopic asthma, have elevated 
PI3K activation, suggesting that PI3K may be an important mediator of eosinophil 
function in asthma78.   
 Neutrophils are present in some, but not all, patients with asthma.  Neutrophilic 
migration and activation releases mediators that contribute to asthma exacerbations.  
PI3K is necessary for neutrophil migration and degranulation in asthma 77,79. 
 
11	  
	  
PI3K Inhibition as a Potential Therapeutic Strategy for Asthma 
 
PI3K has gathered much attention as a potential therapeutic target in asthma as 
outlined in Table 180.  Pan-inhibitors of class I PI3K (wortmannin and LY294002) have 
toxicity profiles and unfavorable pharmacokinetic characteristics, that preclude their 
clinical use81.  The focus, therefore, has shifted to isoform-selective PI3K inhibitors.  
PI3Kα inhibitors have been studied in the treatment of solid tumors but have not been 
approved for clinical use as shown in Table 2 82. PI3Kδ and PI3Kγ, as well as dual 
inhibitors, are promising candidates.  PI3Kγ inhibitors exhibit anti-inflammatory 
properties, but none have been approved for clinical use.  Idelalisib, a PI3Kδ inhibitor, 
has been approved for the treatment of multiple hematologic malignancies.  Side effects 
such as leukopenia, colitis, and skin rashes have occurred upon treatment with 
idelalisib83.  Given the anti-inflammatory and bronchodilator effects, PI3Kδ inhibition 
may be a promising strategy for clinical development, especially with inhaled 
formulations to minimize side effects.  Dual PI3Kδ/PI3Kγ inhibitors have also been 
effective in mitigating inflammatory disorders in animal models, and may be an 
alternate approach81.  IPI-145 (duvelisib) and RV-1729 are PI3Kδ/PI3Kγ combination 
inhibitors that are being developed for clinical use79,84.  TG100-115, another 
PI3Kδ/PI3Kγ combination inhibitor, has been effective in allergen-induced asthma 
models85.  GSK2269557, an inhaled PI3Kδ inhibitor, is being developed for severe 
asthma84. 
AKT and mTORC1 are activated downstream of PI3K and oral inhibitors 
including miltefosine and rapamycin have been developed for clinical use.  None of these 
drugs have been tested for use in airway diseases.  Rapamycin has shown promise in 
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inhibiting mTOR activation in COPD86 and inhibits allergic inflammation in allergen-
challenged mice, while inhibiting eosinophil differentiation 87,88.  
Although promising, PI3K inhibition as a therapeutic strategy is not without 
challenges.  Problems include lack of specificity, adverse effects, and loss of efficacy.  
PI3K inhibitors like most kinase inhibitors target the ATP-binding pocket.  Adequate 
inhibitor potency must be achieved in order to compete with ATP for binding.  The 
structural similarity of the ATP-binding pocket in all kinases makes specific targeting 
difficult.  Having an improved understanding of the ATP-binding pocket structure may 
target the development of inhibitors with improved specificity and potency.  Adverse 
effects occur due to the myriad important functions of PI3K in other tissues.  Inhaled 
delivery systems can promote topical deposition while minimizing system effects.  
Development of inhaled PI3K inhibitors with adequate potency has been difficult, but 
the many preclinical studies and early clinical trials provide hope for future success of 
PI3K inhibition in airway diseases. 
 
Asthma and Bronchodilation 
 
Asthma management has historically focused on: 1) using bronchodilators that 
bind G protein-coupled receptors (GPCRs) to directly inhibit airway smooth muscle 
(ASM) shortening, prevent (bronchoprotect) or reverse bronchoconstriction 
(bronchodilate); and 2) controlling airway inflammation to limit mediators that induce 
ASM contraction or other structural changes that impede airflow (mucus secretion, 
airway edema).  β-2 agonists, the industry standard bronchodilator, bind to the β-2 
adrenergic receptor on airway smooth muscle (ASM) and inducing Gαs-mediated cAMP 
elevation and protein kinase A (PKA) activation.  PKA will then limit signaling pathways 
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that induce ASM shortening such as intracellular calcium mobilization, rho kinase 
(ROCK) activation, and myosin light chain kinase (MLCK) activation.  Unfortunately, 
about 55% of asthmatics have suboptimal control of their symptoms.   
Despite β-2 agonists’ ability to prevent and mitigate asthma exacerbations, they 
have limitations especially concerning efficacy and safety.  Studies have shown that β-2 
agonist use can result in adverse patient outcomes, β-2 adrenergic receptor 
tachyphylaxis, deterioration of asthma control, and death.  New therapeutics are needed 
to overcome these limitations.  New formulations of β-2 agonists offer improved 
specificity and duration of action.  Unfortunately, truly novel therapeutics that overcome 
the limitations of existing drugs have yet to emerge.     
Basic science has identified several novel targets for bronchodilation but none of 
these strategies have translated successfully into clinical utility.  Receptor antagonists 
that block bronchoconstricting agonists include antagonists to the muscarinic, 
histamine, and leukotriene receptors to prevent shortening of ASM.  Due to the 
multitude of bronchoconstricting mediators present in asthma pathology, however, none 
have been uniformly effective.  Several alternative Gαs-coupled receptors have been 
discovered including bitter taste receptors, the pH sensing receptor OGR1, and 
prostaglandin-binding EP receptors.  Regrettably, these receptors lack potent and 
specific ligands, and have similar limitations regarding receptor tachphylaxis. 
 
	  
	  
Rho Kinase and Airway Smooth Muscle 
 
ROCK inhibitors have generated much excitement in the field.  Since ROCK 
activation is necessary to maintain ASM tone by inhibiting MLC phosphatase, ROCK 
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inhibitors allow the constitutively active MLC phosphatase to de-phosphorylate MLC 
and allow relaxation of ASM.  ROCK inhibitors blunt ASM contraction and induce 
bronchodilation in vitro, ex vivo, and in vivo.  The limitation with targeting ROCK is 
that it is ubiquitously expressed, making the potential for undesired side effects high.  
Studies have shown that ROCK can induce hypotension as a result of vasodilation.  
Despite the plethora of promising findings from animal studies that demonstrate 
effective bronchodilation, clinical trials in humans have not been published.  Inhibiting 
ROCK is an effective approach to induce bronchodilation, but strategies need to be 
developed to avoid off target effects.  These strategies can include improved targeting to 
airway smooth muscle, or elucidating the signaling pathways that drive ROCK activation 
in order to identify novel mediators that are not expressed in all smooth muscle cells. 
 
Summary 
 
Asthma represents a syndrome that manifests as immune cell activation, 
inflammatory mediator release, and development of airway obstruction.  PI3K, a crucial 
signaling molecule, plays a role in nearly all aspects of asthma pathophysiology.  
Inhibition of PI3K blunts mucus production, prevents mast cell degranulation, deters 
immune cell recruitment, and facilitates bronchodilation, all of which are therapeutically 
beneficial.  Accordingly, PI3K represents an attractive target for the treatment of asthma. 
This dissertation begins with the observation that PI3K inhibitors promote 
bronchodilation of human small airways (Chapter 2).  To understand this unexpected 
finding, we explore the relationship of PI3K and ROCK in mediating ASM contraction, 
and elucidate the mechanisms by which PI3K inhibitors promote bronchodilation.  We 
then explore the utility of PI3K inhibitors to induce bronchodilation in the contexts of 
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inflammation and β-2 adrenergic receptor tachyphylaxis.  To further understand PI3K 
and ROCK signaling in ASM, we elucidate a signaling pathway leading to GPCR-
mediated PI3K and ROCK activation (Chapter 3).  Through this work, we demonstrate 
for the first time that Gα12 mediates agonist-induced activation of PI3K and ROCK.  
These results reveal a novel pathway regulating PI3K and ROCK signaling that is 
necessary to elicit HASMC shortening.  Importantly, our work has uncovered several 
new targets for bronchodilation and has offered new avenues for the treatment of 
asthma. 
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Figure Legends 
 
Figure 1.  Class I PI3K Signaling.  Class I Phosphoinositide 3-Kinases (PI3K) are 
activated upon agonist binding to Receptor Tyrosine Kinases (RTK) or G-Protein 
Coupled Receptors (GPCR).  RTKs will recruit PI3Ks to phosphorylated tyrosine 
residues, resulting in activation of PI3Ks.  GPCRs can activate PI3Ks via G-proteins such 
as Gα or Gβγ, and through β-Arrestins.  PI3K phosphorylates the D-3 position of the 
plasma membrane lipid phosphatidylinositol-4-5-bisphosphate PI(4,5)P2, generating 
PI(3,4,5)P3.  PI(3,4,5)P3 will recruit proteins with pleckstrin-homology domains which 
include phosphoinositide-dependent kinase 1 (PDK1), AKT Kinase (AKT), Guanine 
Exchange Factors (GEFs), GTPase Accelerating Proteins (GAPs), Tec Family Kinases, 
and Non-Receptor Tyrosine Kinases.  These signaling proteins will subsequently affect 
cellular functions including proliferation, gene expression, anti-apoptosis, cytoskeletal 
rearrangement, and degranulation. 
Figure 2. Functions of Class I PI3K Isoforms in Cells Mediating Asthma 
Pathophysiology.  A schematic representation of the roles of Class I Phosphoinositide 
3-Kinase (PI3K) isoforms in various cell types involved in asthma pathophysiology.  IgE, 
Immunoglobulin Type E; IL-4, Interleukin 4; IL-5, Interleukin 5; Th1, Helper T Cell Type 
1; Th2, Helper T Cell Type 2. 
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Figures  
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Figure 2 
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Table Legends 
 
Table 1.  Characteristics of PI3K in Asthma.  Definition of Abbreviations:  
AHR, Airway Hyperresponsiveness; CXCL-8, C-X-C Motif Chemokine Ligand 8; IgE, 
Immunoglobulin Type E; IL-1, Interleukin 1; IP-10, Interferon Gamma-Induced Protein 
10; MMP-1, Matrix Metallopeptidase 1; PI3K, Phosphoinositide 3-Kinase; P110α, 
Phosphatidylinositol 3-Kinase Catalytic Subunit Alpha Isoform; P110β, 
Phosphatidylinositol 3-Kinase Catalytic Subunit Beta Isoform; P110γ, 
Phosphatidylinositol 3-Kinase Catalytic Subunit Gamma Isoform; P110δ, 
Phosphatidylinositol 3-Kinase Catalytic Subunit Delta Isoform; Th2, Helper T Cell Type 
2; VEGF, Vascular Endothelial Growth Factor. 
Table 2.  PI3K Inhibitors in Clinical Trials for Asthma and COPD.  Definition 
of Abbreviations:  PI3K, Phosphoinositide 3-Kinase; P110α, Phosphatidylinositol 3-
Kinase Catalytic Subunit Alpha Isoform; P110β, Phosphatidylinositol 3-Kinase Catalytic 
Subunit Beta Isoform; P110γ, Phosphatidylinositol 3-Kinase Catalytic Subunit Gamma 
Isoform; P110δ, Phosphatidylinositol 3-Kinase Catalytic Subunit Delta Isoform; 
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Tables 
 
Table 1 
Table 1.  Characteristics of PI3K in Asthma 
Cell/Animal Class I PI3K Subunits Role in Asthma Reference 
Mice p110δ AHR  33-34 
p110δ Inflammation 36 
p110γ Inflammation 37 
p110γ Remodeling 37 
Airway Smooth Muscle p110δ, p110γ Contraction 38-43 
p110α, p110β, p110δ Proliferation 18 
p110α, p110δ Gene Expression 43 
p110γ β-2 Adrenergic Receptor resensitization 44 
p110δ IL-6 secretion 45 
p110α, p110β, p110δ VEGF expression 46 
p110α, p110β, p110δ CXCL-8 expression 47 
p110α, p110β, p110δ MMP-1 secretion 48 
p110α, p110β, p110δ Proliferation 49-53 
Airway Epithelial Cells p110α, p110β, p110δ IP-10 secretion 60 
p110α, p110β, p110δ Nitric oxide signaling 60-61 
p110α, p110β, p110δ Mucus secretion 63 
T Cells p110δ, p110γ Th2 differentiation 27, 64-67 
B Cells p110α, p110β, p110δ, p110γ IgE class-switching 68-69 
Mast Cells p110δ Degranulation 70 
p110γ Cytokine Release 71 
Eosinophils p110γ Chemotaxis 72-73 
p110γ Mediator release 74 
Neutrophils p110δ, p110γ Migration 76 
p110α, p110β, p110δ, p110γ Degranulation 74  
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Table 2 
Table 2.  PI3K Inhibitors in Clinical Trials for Asthma and COPD 
Compound Target Indication Clinical Trial Identifier 
Idelalisib (CAL-101) p110δ Chronic Lymphocytic Leukemia  FDA and EMA approved, 2014 
GSK2269557 p110δ Asthma NCT01462617, Phase 1 
IPI-145 p110δ/p110γ Asthma NCT01653756, Phase 2 
RV-1729 p110δ/p110γ Asthma/COPD NCT01813084, Phase 1 
AQX-1125 SHIP1 activator COPD NCT01954628, Phase 2 
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CHAPTER 2:  Inhibition of PI3K promotes dilation of human small 
airways in a rho kinase-dependent manner  
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Abstract 
	  
Asthma manifests as a heterogeneous syndrome characterized by airway 
obstruction, inflammation and hyperresponsiveness (AHR). Although the molecular 
mechanisms remain unclear, activation of specific PI3K isoforms mediate inflammation 
and AHR. We aimed to determine whether inhibition of PI3Kδ evokes dilation of airways 
and to elucidate potential mechanisms. Human precision cut lung slices from non-
asthma donors and primary human airway smooth muscle (HASM) cells from both non-
asthma and asthma donors were utilized. Phosphorylation of Akt, myosin phosphatase 
target subunit 1 (MYPT1) and myosin light chain (MLC) were assessed in HASM cells 
following either PI3K inhibitor or siRNA treatment. HASM relaxation was assessed by 
micro-pattern deformation. Reversal of constriction of airways was assessed following 
stimulation with PI3K or ROCK inhibitors.  Soluble inhibitors or PI3Kδ knockdown 
reversed carbachol-induced constriction of human airways, relaxed agonist-contracted 
HASM and inhibited pAkt, pMYPT1 and pMLC in HASM. Similarly, inhibition of Rho 
kinase also dilated human PCLS airways and suppressed pMYPT1 and pMLC. Baseline 
pMYPT1 was significantly elevated in HASM cells derived from asthma donors in 
comparison with non-asthma donors. After desensitization of the β2-adrenoceptors, a 
PI3Kδ inhibitor remained an effective dilator. In the presence of IL-13, dilation by a β 
agonist, but not PI3K inhibitor, was attenuated.  PI3Kδ inhibitors act as dilators of 
human small airways. Taken together, these findings provide alternative approaches to 
the clinical management of airway obstruction in asthma. 
 
 
24	  
	  
Introduction 
 
Asthma, a disorder characterized by airway inflammation and airway 
hyperresponsiveness (AHR), globally contributes to substantial morbidity and 
mortality89.  Bronchodilators act either acutely as rescue treatment or chronically as 
maintenance therapy by reversing airway smooth muscle (ASM) shortening and dilating 
airways. While these agents are effective in preventing airflow obstruction, therapeutic 
limitations exist that include increasing sensitivity to bronchoconstrictive agents90, 
receptor tachyphylaxis3,4 and heterogeneity of response imparted by β2-adrenoceptor 
polymorphisms91. Many asthma patients remain poorly controlled with 
bronchodilator(s), suggesting an unmet need for alternative approaches to control 
asthma symptoms and morbidity91,92. 
Phosphoinositide-3 kinase (PI3K), a family of kinases, phosphorylates membrane 
phospholipids. These kinases consist of regulatory subunits p85 and p101, and a catalytic 
subunit p110. Of the catalytic subunits, there are three classes that are differentially 
activated by receptor tyrosine kinases and GPCRs. Class I p110 catalytic subunits include 
α, β, γ and δ and are activated by GPCRs. Evidence suggests that PI3K activation helps 
drive the inflammation associated with allergic airways disease. Inhibition of PI3K 
attenuates allergen-induced eosinophil influx, mucus production26, degranulation of 
bone marrow derived mast cells93 and remodelling of the airways94. Investigators 
previously showed that genetic ablation or inhibition of PI3Kγ or δ isoforms 
substantially decreased AHR36.  In vascular smooth muscle, inhibition of p110α 
attenuated membrane depolarization and contraction of aortic rings by KCl. 
Additionally, inhibition of PI3K class I isoforms with LY294002, wortmannin or targeted 
knockdown of p110α also attenuated KCl-induced phosphorylation and activation of Rho 
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A, myosin phosphatase target subunit 1 (MYPT1) phosphorylation and myosin light 
chain (MLC) phosphorylation95. Rho A and MYPT1 are components of the calcium 
sensitization pathway that amplifies contraction responses in smooth muscle. MYPT1, a 
phosphatase, reverses the phosphorylation of MLC required for smooth muscle 
shortening. Y27632, a Rho kinase inhibitor, also attenuated phosphorylation of MYPT1 
while inhibition of PI3K p110γ attenuated acetylcholine-induced bronchoconstriction of 
murine small airways and calcium flux in murine ASM96. We demonstrated that 
inhibition of PI3Kδ also attenuated TNF-α-induced CD38 expression, an ADP-ribosyl 
transferase that mobilizes cellular calcium97. 
PI3K inhibition prior to stimulation with a contractile agonist attenuated smooth 
muscle contraction, calcium flux44 and other contractile signalling pathways95,98.  For the 
current study, we posit that PI3Kδ inhibition directly dilates human small airways. PI3K 
inhibition, both inhibition of class I p110 subunits [with LY29400299] and targeted 
inhibition of p110δ but not p110γ [with CAL-101100], attenuated carbachol-induced 
phosphorylation of MYPT1 and MLC in human ASM (HASM). Using human precision 
cut lung slices (hPCLS), we show that reversal of carbachol-induced bronchoconstriction 
with PI3K inhibitors or a selective rho-associated protein kinase (ROCK) inhibitor 
[Y27632101] is comparable with that induced by formoterol, a β2-adrenoceptor agonist. 
Interestingly, PI3K inhibition attenuated phosphorylation of MYPT1 and MLC, but had 
little effect on generation of cAMP or agonist-induced calcium mobilization. We show 
that agonist-induced HASM contraction is reversed by both formoterol and CAL-101 to 
similar levels. Modulation of MYPT1 and MLC phosphorylation by PI3K inhibitors is 
receptor dependent, as shown by its absence following KCl stimulation. Following 
salmeterol -induced β2-adrenocpetor desensitization, PI3Kδ inhibition dilates human 
airways more effectively than a β agonist. In a Th2 type inflammatory environment 
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consistent with that observed in asthma, we show that PI3K inhibitors promote airway 
dilation while formoterol-induced airway dilation is attenuated. Additionally, we 
demonstrate that MYPT1 phosphorylation is elevated in HASM derived from fatal 
asthma patients as compared with that derived from non-asthma patients. Taken 
together, these data suggest that the mechanism by which PI3K inhibition 
bronchodilates human airways converges at a step below an elevation in intracellular 
cAMP, thereby providing a complementary therapeutic strategy comparable with β 
agonists for reversing airflow obstruction. 
Methods 
 
Isolation and culture of HASM 
HASM cells were derived from tracheas obtained from the National Disease 
Research Interchange (Philadelphia, PA, USA) and from the International Institute for 
the Advancement of Medicine (Edison, NJ, USA). HASM cell culture was performed as 
described previously102. The cells were cultured in Ham's F-12 medium supplemented 
with 10% FBS, 100 U mL-1 penicillin, 0.1 mg mL-1 streptomycin and 2.5 mg mL-
1amphotericin B, and this medium was replaced every 72 h. HASM cells in subculture 
during passages 1–5 were used, because these cells retain the expression of native 
contractile protein, as demonstrated by immunocytochemical staining for smooth 
muscle actin and myosin102. The HASM cells were derived from donors with fatal asthma 
or from donors who were age- and gender-matched without asthma, as shown in 
Supplemental Table 2. 
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Generation of PCLS and airway dilation assays 
hPCLS were prepared as previously described90. Briefly, whole human lungs from 
non-asthma donors were dissected and inflated using 2% (w v-1) low melting point 
agarose. Once the agarose set, the lobe was sectioned, and cores of 8 mm diameter were 
made. The cores that contained a small airway by visual inspection were sliced at a 
thickness of 350 µm (Precisionary Instruments VF300 Vibratome, Greenville, NC, USA) 
and collected in wells containing supplemented Ham's F-12 medium. The cores 
generated were randomized as to the location in the lungs they were derived from, so the 
slices generated came from throughout the lungs and not one specific area. This 
generated variation in the slices both from within a single donor, and also accounts for 
variation from donor to donor. Suitable airways (≤1 mm diameter) on slices were 
selected on the basis of the following criteria: presence of a full smooth muscle wall, 
presence of beating cilia and unshared muscle walls at airway branch points to eliminate 
possible counteracting contractile forces. Each slice contained ∼98% parenchyma tissue; 
hence, all airways situated on a slice had sufficient parenchymal tissue to impart basal 
tone. Slices containing contiguous segments of the same airway served as controls and 
were incubated at 37°C in a humidified air-CO2 (95–5%) incubator. Sections were rinsed 
with fresh media 2–3 times on days 1 and 2 to remove agarose and endogenous 
substances released that variably confound the production of inflammatory mediators 
and/or alter airway tone90. Airways from each core were randomized to the different 
treatment groups prior to the start of the experiment. Airways were constricted to a dose 
response of carbachol (10−8–10−5 M), then dilated to one of the following (10−11–10−4 M): 
diluent (DMSO), formoterol, isoprenaline, LY294002, CAL-101 or Y27632. DMSO alone 
did not induce airway dilation at the concentrations tested (data not shown). 
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To assess luminal area, lung slices were placed in a 12-well plate in media and 
held in place using a platinum weight with nylon attachments. The airway was located 
using a microscope (Nikon Eclipse; model no. TE2000-U; magnification, ×40) 
connected to a live video feed (Evolution QEi; model no. 32-0074A-130 video recorder). 
Airway luminal area was measured using Image-Pro Plus software (version 6.0; Media 
Cybernetics) and represented in mm2 90. After functional studies, the area of each airway 
at baseline and at the end of dose the response was calculated using Image-Pro Plus 
software. Maximal airway dilation (Emax), sensitivity of the airways to contractile agonist 
– log of the effective concentration to induce 50% airway dilation (log EC50) and the 
integrated response to dilatory agonist – AUC were calculated from the dose-response 
curves generated. The hPCLS were derived from non-asthma donors, as shown in 
Supplemental Table 3. Airway dilation was calculated as % reversal of maximal 
bronchoconstriction. Time courses of airway dilation to Y27632, CAL-101 and formoterol 
were performed to show the kinetics of response of the airways to reversal of carbachol-
induced airway constriction by these compounds (Supplemental Figure 1). 
 
Immunoblot analysis 
HASM cells were treated with LY294002, CAL-101 or Y27632 (1 µM for time 
course experiments – 0–60 min, or 10−8–10−6 M for 30 min for dose response 
experiments) then stimulated with carbachol (10 µM – 10 min). Cells were then treated 
with 500 µM perchloric acid, plates scraped and cells pelleted. Pellets were solubilized in 
RIPA and sonicated prior to being subjected to SDS-PAGE and transferred to 
nitrocellulose membranes, as previously described103. Phosphorylation of MYPT1, MLC 
and Akt were assessed, and band densities were normalized to total tubulin band 
density.  A total of 5–7 individual donor cell lines for derived from either non-asthma or 
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fatal asthma donors were used in these experiments. Total protein expression of MYPT1, 
MLC and Akt were also assessed in the same lysates (Supplemental Figure 2). 
 
Contractility measurements of individual HASM cells 
Soft silicone elastomer films were micro-patterned with fibronectin and 
fluorescent fibrinogen in uniform ‘X’ shapes (70 µm diagonal by 10 µm thick). These 
substrates were prepared using a robust sacrificial approach to facilitate covalent 
embedding of the extracellular matrix (ECM) molecules into the film as previously 
described104. The non-patterned regions were blocked using 0.5% Pluronic F-127 
preventing cell adhesion outside of the fibronectin patterns. Isolated cells adhering to 
these ‘X’-shaped micro-patterns exerted tonic traction forces or stimulated contraction 
forces, resulting in deformations of the micro-patterns (Figure 3A). Dimensions of 
contracted micro-patterns, which correspond directly to the force applied on them by 
adhered cells, relative to the original unperturbed dimensions were used to assess 
cellular contractile responses to the tested compounds. Prior to stimulation, isolated 
HASM cells were seeded on the soft substrates, allowed to adhere and serum-starved for 
48 h. Cells were then stimulated with bradykinin (10−6 M, 15 min) to induce contraction 
and treated with 0.5% v v-1 DMSO in medium (control), formoterol or CAL-101 (10−10, 
10−7 or 10−4 M). Each condition was performed in triplicate wells for a non-asthmatic 
HASM cell line. The fluorescent micro-patterns were imaged immediately before 
stimulation with bradykinin for a baseline reading, and approximately 15 min after 
administration of the treatments. Cell nuclei were stained with Hoechst 33342 prior to 
imaging, and only the patterns co-localized with exactly one stained nucleus were used in 
the analysis. Following these studies, matlab (Mathworks, Natick, MA, USA) was used to 
measure each individual pattern and generate distributions of the relative contractions 
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of the patterns for each treatment case. Using the medians of these distributions, the 
relative relaxation was calculated as the percent reversal from maximal contraction. 
Bradykinin was administered at 10−4 M in the movies provided in the supplemental 
materials, but lowered to 10−6 M in the experimental data shown. 
 
Statistical analysis 
The data and statistical analysis comply with the recommendations on 
experimental design and analysis in pharmacology105. GraphPad Prism software (La 
Jolla, CA, USA) was used to determine statistical significance evaluated by Student's 
paired t-test for two groups or ANOVA for multiple groups. P values of <0.05 were 
considered significant. For lung slice analysis (Figures 1, 5, and 8), slices were not 
compared with themselves for each treatment group, so repeated measures analysis was 
not used. Data were found to be normally distributed, and ANOVAs were used for data 
analysis, with Bonferroni's post-test. Unpaired t-tests with Welch's correction were used 
after ANOVAs had established significance to compare each inhibitor with formoterol, 
and conditions within a given inhibitor stimulation (for example, −/+ IL-13 for 
LY294002-induced airway dilation). For Figure 7, results were analysed by two-way 
repeated measures ANOVA with desensitization pretreatment (control or salmeterol) as 
Factor A and bronchodilator test compound (isoprenaline or CAL-101) as Factor B. The 
data passed the normality, and equal variance tests and significant effects of both factors 
were detected. Differences were isolated using the Bonferroni t-test for all pairwise 
comparisons. Immunoblot data and single cell contractile data were analysed by 
Student's two-tailed t-tests. SigmaStat (Systat, San Jose, CA, USA) and GraphPad 
Prism programmes were used in statistical analyses.  
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Materials 
Carbachol (carbamoyl choline chloride), formoterol (formoterol fumarate 
dihydrate), isoprenaline (ISO – isoproterenol hydrochloride), salmeterol (salmeterol 
xinafoate), bradykinin (bradykinin acetate salt) and perchloric acid were purchased from 
Sigma Aldrich (St. Louis, MO, USA). LY294002 was purchased from Cayman Chemical 
Company (Ann Arbour, MI, USA), and CAL-101 was purchased from Selleck Chemicals 
(Houston, TX, USA). Y27632 was purchased from Enzo Life Sciences (Farmingdale, NY, 
USA). Rho activity assay kit was purchased from Cytoskeleton (Denver, CO, USA). 
Constructs (siRNA) targeting PI3K p110γ and δ were purchased from Qiagen (The 
Netherlands). Antibodies for detection of pMYPT1-Thr696 (5163S), pAkt (4060S), pMLC 
(3674S) and tubulin (3873S) were purchased from Cell Signalling Technologies 
(Danvers, MA, USA). Pharmacological properties of the inhibitors utilized in these 
studies are found in Supplemental Table 1. 
 
Results 
 
PI3K inhibition reverses carbachol-induced constriction of human small 
airways in a dose-dependent manner 
To determine if inhibition of PI3K dilates precontracted small human airways, 
PCLS were prepared from donors with no history of lung disease. PCLS airways were 
treated with carbachol to induce bronchoconstriction and then treated with increasing 
doses of LY294002, CAL-101 or formoterol to evaluate airway dilation (Figure 1). Both 
LY294002 and CAL-101 markedly reversed carbachol-induced bronchoconstriction, but 
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it was not to the same level as to the β agonist formoterol. Further, we evaluated ROCK 
and PI3K inhibitor-induced airway dilation and detected responses as early as 5–10 min, 
which were sustained through 30 min following a single dose of inhibitor (Supplemental 
Figure 1). LY294002 and CAL-101 also reversed bronchoconstriction induced by 
histamine (data not shown). Pretreatment with these inhibitors had little effect on 
carbachol-induced calcium transients in HASM cells (Supplemental Figure 3). These 
data indicate that inhibition of the p110 subunit of PI3K and specifically of p110δ is 
bronchodilatory and that the mechanism likely involves events distal to the activation of 
GPCRs mediating bronchoconstriction in human airways. 
 
PI3K inhibition attenuates carbachol-induced phosphorylation of Akt, 
MYPT1 and MLC 
Phosphorylation of key components of excitation-contraction coupling pathways, 
including Akt (a surrogate to measure PI3K activation), MYPT1 and MLC mediate 
agonist-induced HASM shortening. Conversely, dephosphorylation of these targets 
promotes lengthening of HASM. Accordingly, carbachol-induced activation 
(phosphorylation) of Akt, MYPT1 and MLC were examined in HASM in the presence and 
absence of PI3K inhibition. As shown in Figure 3, selective PI3Kδ inhibition with CAL-
101 (Figure 2A) or a pan-PI3K inhibitor LY294002 in HASM cells (Figure 2B) inhibited 
carbachol-induced phosphorylation of Akt, MYPT1 and MLC in a time- (Figure 2A and 
B) and dose-dependent manner (Figure 2C). To assess whether membrane 
depolarization-induced phosphorylation of Akt, MYPT1 and MLC required PI3K 
activation, HASM cells were treated with KCl in presence or absence of CAL-101 (Figure 
2D). Unlike carbachol-induced phosphorylation of MYPT1 and MLC, KCl-dependent 
phosphorylation of MYPT1 and MLC was unaffected by CAL-101 while phosphorylation 
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of Akt was PI3K-dependent. These data suggest that the mechanism for smooth muscle 
contractile responses to membrane depolarization by KCl is either parallel or it 
converges below PI3K and MYPT1 phosphorylation on phosphorylation of MLC. 
 
PI3K inhibition reverses bradykinin-induced shortening of single HASM 
cells 
To determine if inhibition of PI3K reverses contractile agonist-induced 
shortening of single HASM cells, cells were seeded on fluorescently micro-patterned soft 
silicone elastomer substrates, stimulated with bradykinin to induce shortening and then 
treated with increasing doses of CAL-101 or formoterol. Relaxation of the cells was 
evaluated, and we show that CAL-101 reversed bradykinin-induced shortening 
comparable with maximal levels induced by formoterol Figure 3. 
 
Suppression of PI3K p110δ protein expression inhibits –carbachol-induced 
phosphorylation of MYPT1 and MLC 
Murine models showed that genetic ablation of PI3K p110γ or δ attenuated 
airway hyperreactivity after allergen challenge36,44. We demonstrated that carbachol-
induced phosphorylation of contractile proteins is attenuated by pharmacological 
inhibition of PI3K p110, specifically p110δ. We next sought to define the requirement for 
p110δ in modulating phosphorylation events mediating HASM shortening by using 
siRNA targeting PI3K p110δ to suppress protein expression in HASM cells (Figure 4A). 
As a consequence, carbachol-induced phosphorylation of both MYPT1 and MLC were 
significantly reduced (Figure 4B). However, knockdown of PI3K p110γ had little effect on 
phosphorylation of MYPT1 and MLC (Supplemental Figure 4). Knockdown of either 
PI3K p110δ or p110γ reduced carbachol-induced Akt phosphorylation, but this was not 
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statistically significant. The limitation to these observations is that although we detected 
expression of PI3Kδ, we could not detect PI3Kγ in HASM. Taken together, 
pharmacological inhibition and siRNA-mediated suppression indicate that p110δ likely 
mediates distal events regulating ASM shortening in response to carbachol. 
 
Inhibition of rho kinase with Y27632 induces airway dilation of human 
small airways and attenuates activation of rho kinase and phosphorylation 
of MLC 
In vascular smooth muscle, PI3K p110α regulates Rho activation and MYPT1 
phosphorylation95. Rho kinase (ROCK) activation plays a role in the maintenance of 
airway muscle tone in guinea pig ileum106 and pig trachea107 strips. To determine if 
ROCK activation similarly mediates maintenance of airway tone in carbachol 
bronchoconstricted PCLS airways, we treated hPCLS with increasing doses of the ROCK 
inhibitor Y27632 and observed that Rho kinase inhibition evoked airway dilation similar 
to that observed with the β agonist formoterol, but not quite as robust. Like LY294002 
and CAL-101, Y27632 induced dose-dependent airway dilation (Figure 5A). ROCK 
inhibition also attenuated carbachol-induced phosphorylation of MYPT1 and MLC, but 
not Akt in HASM cells (Figure 5B and C). To define the role for ROCK in receptor-
independent contraction, HASM cells were also treated with KCl in the presence or 
absence of Y27632. As shown in Figure 5D, inhibition of ROCK activity attenuated 
receptor-independent phosphorylation of MYPT1 and MLC. These data indicate that 
while Rho kinase activation by carbachol occurs either downstream or parallel to PI3K 
activation, both converge on MYPT1 and MLC phosphorylation. 
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Baseline rho kinase activity is increased in HASM derived from asthma 
donors 
The present studies point to MYPT1 phosphorylation as an important mechanism 
mediating a procontractile phenotype. As compared with normal donors, HASM cells 
derived from asthma donors retain a phenotype consistent with asthma manifested by 
hypersecretion of inflammatory mediators, growth and proliferation85,108–112. Therefore, 
we evaluated MYPT1 activation in HASM cells from non- and fatal asthmatic donors. As 
shown in Figure 6A, HASM cells derived from asthma donors exhibit greater baseline 
phosphorylation of MYPT1 in comparison with HASM cells derived from non-asthma 
donors. In parallel, we found that ROCK activity levels were also elevated in HASM cells 
derived from asthma donors (Figure 6B). These data suggest that there is a greater 
activation of Rho kinase-dependent pathways evoking MYPT1 phosphorylation in HASM 
cells from donors with asthma. 
 
PI3K and rho kinase inhibitors induce airway dilation after β2AR 
desensitization or IL-13 stimulation 
To determine the potential benefit of pharmacological inhibition of PI3K and 
ROCK as ‘rescue’ bronchodilators, we evaluated responses of hPCLS desensitized to a β 
agonist or maintained in a Th2-like inflammatory environment, elevated levels of IL-13. 
Tachyphylaxis of the β2-adrenoceptor limits the therapeutic efficacy of β agonists in 
airways disease113,114.  Because this involves a proximal event (failure to activate of Gsα), 
we hypothesized that PI3K inhibition would induce airway dilation despite β2-
adrenoceptor tachyphylaxis. In hPCLS treated for 24 h with salmeterol, isoprenaline 
failed to reverse carbachol-induced bronchoconstriction (Figure 7), implying 
tachyphylaxis. By contrast, CAL-101 effectively dilated airways despite impaired β2-
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adrenoceptor activation. Inhibition of PI3K alone or in combination with isoprenaline 
had no direct effect on generation of cAMP in HASM (Supplemental Figure 5). 
We previously demonstrated that IL-13, an important Th2 inflammatory 
mediator in asthma, attenuates β2-adrenoceptor agonist-induced airway dilation90, but 
has little effect on airway dilation to the TAS2 receptor agonist chloroquine115. 
Accordingly, we posited that IL-13 may limit PI3K inhibitor-mediated airway dilation of 
carbachol-constricted hPCLS. While formoterol-induced airway dilation was attenuated 
by IL-13 treatment, PI3K inhibitor-induced airway dilation was not affected significantly 
by IL-13 (Figure 8). Taken together, these experiments using hPCLS define new 
therapeutic approaches to bronchodilation. 
 
Discussion 
 
Asthma, a chronic respiratory disorder marked by inflammation, recurrent 
reversible airflow obstruction and AHR, remains a significant cause of morbidity and 
mortality89. Despite efficacy of both long- and short-acting bronchodilators, a significant 
number of asthma patients remain uncontrolled due to a number of factors including 
tachyphylaxis of the receptor3,4, genetic polymorphisms altering receptor function or 
heterogeneity of patient responses91,92. There exists an unmet need for alternative 
methods to induce bronchodilation that are independent of the β2-adrenoceptor. 
Studies in murine models of allergen challenge showed a role for class I PI3K 
p110γ and δ isoforms in trafficking/activating inflammatory cells, decreasing mucus 
production and attenuating AHR following allergen challenge26,93,94. Interestingly, 
inhibition of PI3K p110δ, either by genetic ablation26 or by pretreatment with a δ 
selective pharmacological inhibitor44, had little effect on baseline methacholine-induced 
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bronchoconstriction in vivo or in ex vivo murine lung slices. A PI3Kγ selective inhibitor 
attenuated acetylcholine-induced bronchoconstriction of murine precision cut lung slices 
and calcium flux in murine ASM cells44. We now show that pretreatment of HASM cells 
with either LY294002 or CAL-101 had little effect on calcium flux in HASM cells 
(Supplemental Figure 3). We provide evidence of PI3K p110δ, but not γ, isoform 
expression in ASM97 [Supplemental Figure 2], validating our approach to selectively 
targeting PI3K p110δ in modulation of contractile pathways in HASM and airway 
dilation in PCLS. In addition to using human cells and PCLS, our study also focused on 
using PI3K inhibitors to induce airway dilation rather than on using PI3K inhibition as a 
bronchoprotective agent. We show that in human airways, inhibition of PI3K p110 
isoforms with LY294002, as well as selective inhibition of p110δ with CAL-101, promotes 
airway dilation comparable with the β agonists isoprenaline or formoterol. Clinically, the 
onset of action for formoterol is within 1–4 min following inhalation116. In contrast, 
airway dilation in response to a PI3K or ROCK inhibitor is slower given these 
compounds act on intracellular targets rather than a cell surface receptor. We 
demonstrate that the time scale of inhibitor-induced dilation of carbachol-constricted 
airways is in agreement with the time course of PI3K or ROCK inhibition of carbachol-
induced phosphorylation of Akt, MYPT1 and MLC (Figures 1, 2, and 5) and Supplemental 
Figure 1. As a surrogate for airway constriction and relaxation, we utilized a novel in 
vitro approach measuring contractility of single HASM cells to assess the effect of PI3K 
inhibition on cellular dynamics of contraction and relaxation (Figure 3A). Using this 
system, we show that both formoterol and CAL-101 induce relaxation of HASM cells that 
have been precontracted by bradykinin in a dose-dependent manner (Figure 3B).  In this 
system, we show that there is no significant difference in the maximal relaxation elicited 
by formoterol or CAL-101. These data suggest that CAL-101 is as effective of a HASM 
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relaxant as formoterol at a maximal concentration. These data provide alternative 
mechanisms/targets for inducing airway dilation in humans that are independent of β2-
adrenoceptor activation. 
In vascular smooth muscle, the PI3K p110α isoform regulates Rho activation and 
phosphorylation of MYPT1 and MLC in response to KCl95. Others demonstrate that in 
response to histamine, phosphorylation of MLC in vascular smooth muscle is PI3K-
dependent98. To determine potential mechanisms by which inhibition of PI3K induces 
airway dilation, we examined carbachol-induced phosphorylation of Akt (as a marker of 
PI3K activation), MYPT1 and MLC. Carbachol-induced Akt, MYPT1 and MLC 
phosphorylation was inhibited by CAL-101 and LY294002 in a time- and dose-
dependent manner. To assess the contribution of PI3K p110 isoforms to non-receptor-
mediated activation of contractile pathways, we also stimulated HASM cells with KCl in 
the presence and absence of pharmacological inhibition of PI3K. We demonstrated that 
phosphorylation of MLC and MYPT1 are independent of PI3K activation in response to 
KCl. These data provide a mechanism by which carbachol-induced bronchoconstriction 
is reversed by PI3K inhibition, but that receptor-independent stimulation of contractile 
pathways with KCl is PI3K-independent unlike in vascular smooth muscle98. The 
physiological relevance of KCl-induced phosphorylation of Rho kinase and MLC remains 
unclear117. Additionally, we demonstrated that knockdown of PI3K p110δ attenuates 
carbachol-induced phosphorylation of MLC and MYPT1. We showed that PI3K p110δ, 
but not γ, is expressed in HASM cells and that inhibition of PI3K isoforms has no effect 
on expression of levels of total Akt, MYPT1 or MLC proteins. Additionally, we 
demonstrated that knockdown of PI3Kγ in HASM cells has little effect on carbachol-
induced phosphorylation of Akt, MYPT1, and MLC. Given the lack of specific antibodies, 
we cannot completely rule out the possibility that the PI3K p110γ isoform may also play 
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role in relaxation of ASM, but given the data we have concerning lack of its expression in 
isolated smooth muscle, we feel that this is unlikely. 
β-adrenoceptor agonists induce bronchodilation by generating cAMP and 
activating protein kinase A that inhibit, in part, MLC kinase and phosphorylation of 
MLC. To determine whether PI3K inhibition affects the phosphorylation status of MLC 
through generation of cAMP, we treated HASM cells with LY294002 and CAL-101 in the 
presence or absence of isoprenaline and assessed cAMP generation (Supplemental 
Figure 5). We showed that treatment with the PI3K inhibitors has little effect on cAMP 
generation and that pretreatment with the inhibitors prior to isoprenaline stimulation 
also had little effect. These data suggest that PI3K inhibitor-induced airway dilation is 
independent of inducing or potentiating β2 agonist-induced cAMP production. 
Additionally, we showed that PI3K inhibition does not appear to directly affect 
carbachol-induced calcium transients in HASM (Supplemental Figure 3). 
Given evidence in vascular smooth muscle linking PI3K and Rho pathways118, we 
sought to determine whether Rho kinase inhibition attenuated constriction of human 
small airways and excitation-contraction pathways activated in HASM cells. We found 
that Y27632, a Rho kinase inhibitor, reversed carbachol-induced bronchoconstriction to 
levels comparable with that observed using PI3K inhibitors (Figure 5A). We also showed 
that phosphorylation of MYPT1 and MLC, but not Akt, are inhibited by the ROCK 
inhibitor Y27632 in a time- and dose-dependent manner (Figure 5B and C). In assessing 
the effect of Rho kinase inhibition on receptor-independent activation of contractile 
pathways, however, we found that Y27632 attenuated KCl-dependent phosphorylation of 
MYPT1 and MLC (Figure 5D). These data suggest that receptor-dependent and receptor-
independent contractile pathways activate ROCK and MLC but that receptor-dependent 
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pathways also activate PI3K that requires Rho kinase to mediate contractile responses, 
as illustrated in Figure 9. 
Given both clinical92 and experimental evidence113 demonstrating agonist-
induced desensitization of the β2-adrenocpetor and tachyphylaxis, we posited that 
inhibition of contractile pathways downstream from the receptor and independently of 
the β2-adrenoceptor-mediated pathways would induce airway dilation. While 
pretreatment of PCLS with salmeterol diminished airway dilation to isoprenaline, CAL-
101 retained the ability to dilate human small airways despite impaired β2-adrenoceptor 
activation (Figure 7). While we presume that this is due to receptor desensitization, it is 
could also be a manifestation of the antagonistic properties of residual lipophilic 
salmeterol remaining in the tissue despite washout119,120.  Carbachol-induced airway 
constriction in these slices were comparable between the salmeterol-treated and non-
treated airways, indicating that the bronchoprotective properties of salmeterol treatment 
were not retained after washing of the tissue. 
The inflammatory milieu in asthma engenders AHR to contractile agonists and 
attenuates β2 agonist-induced bronchodilation47,90,121. Previously, we showed that 
exposure to IL-13 renders airways hyposensitive to β2-adrenoceptor agonist-mediated 
airway dilation but not TAS2 receptor-mediated airway dilation115. Our data show that in 
the presence of IL-13, PI3K inhibitor-dependent airway dilation retained efficacy while 
β2 agonist-mediated airway dilation was partially inhibited. Farghaly et al. demonstrated 
that IL-13 augmented carbachol-induced contractility of murine tracheal rings and that 
this hyperresponsiveness was mediated by PI3K p110 isoforms, specifically PI3K p110δ45. 
We previously reported that IL-13 augments carbachol-induced airway narrowing and 
attenuates β2-adrenoceptor agonist-induced airway dilation in human PCLS90,115. 
Although IL-13 attenuates β2-adrenoceptor agonist-induced airway90,115,121–123, IL-13 has 
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little effect on PI3K p110 inhibitor-induced airway dilation as shown in Figure 8. We and 
others have shown that HASM cells derived from fatal asthma donors manifest distinct 
phenotypes compared to cells derived from non-asthmatic patients, including cell 
proliferation110, enzymatic function124,125, receptor signalling and sustained calcium 
transients consistent with contractility of the muscle108,111,126. We now show that 
phosphorylation of MYPT1, a phosphatase that regulates MLC phosphorylation and 
HASM cell shortening, is elevated at baseline in asthma-derived HASM cells (Figure 6). 
Phosphorylation of MYPT1 inactivates this key signalling event of calcium sensitization. 
We also demonstrated that endosomes from asthma-derived HASM cells, as compared 
with non-asthma HASM cells, manifest increased PI3Kγ activation and a reduction in 
protein phosphatase 2A activity that inhibits β2-adrenoceptor resensitization47. 
Collectively, these findings have implications providing a plausible hypothesis as to why 
β2 agonists are less effective in Th2 airway inflammation127. Moreover, our data suggest 
that in a Th2 inflammatory milieu promoting AHR, PI3K inhibitors retain efficacy as 
bronchodilators while β agonist responses are attenuated. 
Our data suggest that both PI3K and ROCK inhibitors induce airway dilation. 
Because others have suggested that PI3K inhibitors may also act as anti-inflammatory 
agents in asthma, PI3K activation may serve as a unique therapeutic target in asthma 
and chronic obstructive pulmonary disease to attenuate airway inflammation and 
promote airway dilation. 
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Figure Legends 
 
Figure 1.  PI3K inhibition reverses carbachol-induced bronchoconstriction 
in a dose-dependent manner in hPCLS.  Airways were preconstricted to carbachol 
(10−8–10−4 M) prior to dilation to LY294002, CAL-101 or formoterol (10−11–10−5 M). 
Maximal airway dilation (Emax, ANOVA, P = 0.03) and AUC (P = 0.004) for each 
inhibitor was significantly different than formoterol-induced dilation. Data are 
representative of n ≥ 5 donors, 26–33 slices per condition, with bars representing 
mean + SEM. 
Figure 2. PI3K inhibition blocks carbachol-induced MYPT1 and MLC 
phosphorylation in HASM cells.  Time-dependent inhibition of carbachol-induced 
(10 min, 10 µM) MYPT1 and MLC phosphorylation in HASM cells by CAL-101 (A) and 
LY294002 (B) (1 µM). Data are representative of five different HASM donors (n = 5 
donors, mean ± SEM). *P < 0.05. P values are time points compared with basal. (C) 
Concentration-dependent inhibition of carbachol-induced MYPT1, Akt and MLC 
phosphorylation in HASM cells by LY294002 and CAL-101. Data are representative of 
five different HASM donors. *P < 0.05. P values compared with basal (n = 5, 
mean ± SEM). (D) CAL-101 (1 µM) prevents carbachol- (10 min, 10 µM).  
Figure 3. PI3K inhibition reverses bradykinin-induced shortening in 
isolated HASM cells.  Cells were stimulated to contract with bradykinin (10−6 M) prior 
to treatment with 0.5% v v-1 DMSO control, or formoterol or CAL-101(10−10, 10−7 and 
10−4 M). (A) Representative images of fibronectin micro-patterns on ultra-soft silicone 
elastomer films. Top: typical uncontracted and contracted micro-patterns. HASM F-
actin is shown in green. Bottom: averaged patterns for each treatment case generated 
from one pattern taken from each of the nine imaging sites used per sample. (B) 
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Quantification of cell relaxation to formoterol or CAL-101 (10−10, 10−7 and 10−4 M) 
following bradykinin contraction. Bars represent mean of the triplicates + SEM, with 
each column representing ≥720 cells analysed per triplicate well measurement from a 
single donor. P < 0.05 was considered significant. 
Figure 4.  siRNA knockdown of PI3K p110δ prevents carbachol-induced 
(10 min, 10 µM) MLC phosphorylation (pMLC) by suppression of ROCK in 
HASM cells.  (A) Immunoblot analyses of HASM cells transfected with PI3K p110δ 
siRNA or scrambled siRNA. (B) Inhibition of carbachol-induced phosphorylation of 
MYPT1 (pMYPT1) and MLC (pMLC) in HASM cells by PI3K p110δ siRNA. Data are 
representative of five independent experiments (n = 5, mean + SEM); *P < 0.05. 
 
Figure 5. Rho Kinase inhibition induces airway dilation in hPCLS and 
inhibits carbachol-induced MYPT1 and MLC phosphorylation in HASM cells. 
(A) hPCLS were bronchoconstricted with carbachol (n = 12 donors) and sequentially 
treated with 0.02% DMSO (Veh) or increasing concentrations of Y27632 (10−11 – 10−5 M). 
Data are representative of n ≥ 5 separate donors (two-tailed t-test P = 0.02 for 
Emax, P = 0.001 for AUC). (B) Time-dependent inhibition of carbachol-induced (10 min, 
10 µM) phosphorylation of MYPT1 (pMYPT1) and MLC (pMLC) in HASM cells by 
Y27632 (1 µM). Data are representative of five different HASM donors (n = 5, 
mean + SEM). *P < 0.05. P values are time points compared with vehicle control. (C) 
Concentration-dependent inhibition of carbachol-induced phosphorylation of MYPT1 
and MLC in HASM cells by Y27632 (30 min pretreatment, 10−8–10−6 M). Data are 
representative of five independent experiments. *P < 0.05. P values compared with 
vehicle control. (D) Y27632 (1 µM) prevents carbachol- (10 min, 10 µM) and KCl- 
(10 min, 50 mM) mediated pMYPT1 and pMLC, but has little effect on Akt 
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phosphorylation in primary HASM cells. Data are representative of five different HASM 
donors (n = 5, mean + SEM). 
 
Figure 6.  Rho kinase activation is greater in HASM cells obtained from 
subjects with asthma as compared to those of non-asthmatic subjects. HASM 
cells obtained from fatal asthmatic and non-asthmatic subjects were lysed and subjected 
to immunoblot for phosphorylated MYPT1 (A), or elisa to measure ROCK activation (B). 
Data represent mean + SEM fold change of MYPT1 phosphorylation as compared with 
tubulin control (immunoblotting) and fold compared with basal (for elisa). 
*P < 0.05. n = 7 asthma and seven non-asthma for (A). n = 5 asthma and seven non-
asthma for (B). 
 
Figure 7.  PI3K inhibition induces airway dilation of small airways despite 
desensitization of the β2-adrenoceptors. hPCLS from four separate donors 79–81 
slices/condition, total of 160 slices, were incubated in the presence or absence of 50 nM 
salmeterol (SALM; 24 h) to induce desensitization of the β2-adrenoceptor. After washout 
and treatment with carbachol, isoprenaline (ISO)-induced airway dilation was 
significantly attenuated by salmeterol pretreatment. CAL-101-induced airway dilation, 
however, was indistinguishable from control pretreatment and was enhanced compared 
with the previous treatment of β agonist-desensitized airways. Data are presented as 
mean + SEM *P < 0.05. 
 
Figure 8.  PI3K inhibition induces airway dilation of small airways despite 
inflammation.  PI3K and ROCK inhibitor-induced airway dilation in the presence and 
absence of IL-13. hPCLS were incubated in the presence or absence of IL-13 
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(100 ng·mL−1, 18 h), precontracted to ~60–70% of baseline luminal area and relaxed to a 
dose response of LY294002, CAL-101 or the β2-adrenoceptor agonist formoterol (10−11–
10−5 M). AUC was compared between control and IL-13 treatment for each compound 
used to dilate the airways. Data are representative of n ≥ 4 donors, 5–44 slices per 
condition, with bars representing mean + SEM, with P ≤ 0.05 considered significant 
(ANOVA P = 0.01; two-tailed t-tests: control versus IL-13 for formoterol P = 0.009, 
control versus IL-13 for CAL-101 P = n.s., control versus IL-13 for LY294002 P = n.s.). 
 
Figure 9.  An overview of the signalling mechanisms underlying PI3K and 
ROCK inhibitor-mediated airway dilation of HASM cells.  IP3, inositol 
triphosphate; RyR, ryanodine receptor; MLCK, MLC kinase. 
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Figure 5 
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Figure 8 
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Figure 9 
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Supplemental Figure Legends 
 
Supplemental Figure 1.  Time course of airway dilation to CAL-101 and 
Y27632. Airways in lung slices were preconstricted to carbachol, then dilated to CAL-
101 or Y27632 (60 µM), 0–30 min. Data is representative of mean ± SEM for 4–15 
slices/condition. 
 
Supplemental Figure 2.  PI3K p110δ (A) and γ (B) mRNA expression in 
airway smooth muscle assessed by RNAseq. PI3K inhibition has little effect on 
expression of total protein levels (C) of MYPT1 (D), Akt (E), and MLC (F). Data is 
representative of n = 5–8 (A and B) or n = 2 (C-F) HASM cell lines. 
 
Supplemental Figure 3.  PI3K inhibition has little effect on agonist-induced 
calcium mobilization.  HASM were stimulated with 10 µM carbachol following a 
30 min pretreatment with vehicle (DMSO), CAL-101 or LY294002 (1 µM) and single cell 
calcium transients measured using Fluo-8 calcium sensing dye. (A) Time course tracings 
of calcium flux. Both peak calcium (B) and AUC (C) for each treatment were plotted as 
mean ± SD. 
 
Supplemental Figure 4.  siRNA knockdown of PI3K p110γ had little effect on 
carbachol-induced (10 min, 10 µM) phosphorylation of MLC (pMLC), 
MYPT1, or Akt in HASM cells. (A) Immunoblot analyses of HASM cells transfected 
with PI3K p110γ siRNA or scrambled siRNA. 3 (B) Slight inhibition of carbachol-induced 
phosphorylation of Akt (pAkt) and MYPT1 (pMYPT1) in HASM cells by PI3K p110δ 
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siRNA. Data are representative of five independent experiments (n = 5, mean + SEM); 
*P < 0.05. 
 
Supplemental Figure 5.  PI3K inhibition has little effect alone to induce or 
augment cAMP levels. Data are representative of 3 donors and each condition in 
triplicate, with bars representing mean ± SEM with a P value of <0.05 considered 
significant. 
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Supplemental Figures 
 
Supplemental Figure 1 
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Supplemental Figure 2 
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Supplemental Figure 3 
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Supplemental Figure 4 
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Supplemental Figure 5 
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Supplemental Table Legends 
 
Supplemental Table 1. Pharmacologic properties of the inhibitors utilized in 
this study. In vitro kinase assay results, IC50values in cell based assays, and the 
corresponding literature citations are shown for CAL-101, LY294002, and Y27632. 
 
Supplemental Table 2.  Donor demographics of non-asthma hPCLS donors. 
 
Supplemental Table 3.  Donor demographics of asthma and non-asthma 
HASM cell donors. 
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Supplemental Tables 
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CHAPTER 3:  Gα12 Facilitates Methacholine-Induced Shortening in 
Human Airway Smooth Muscle By Modulating Phosphoinositide 3-
Kinase-Mediated Activation In A RhoA-Dependent Manner 
 
 
Edwin J. Yoo1, Gaoyuan Cao1, and Reynold A. Panettieri Jr.1 
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Abstract 
	  
Asthma manifests as airway hyperresponsiveness and inflammation.  
Importantly, G-protein-coupled receptors (GPCRs) regulate contraction of the human 
airway smooth muscle cell (HASMC), the pivotal cell regulating bronchomotor tone.  
Although  PI3K-dependent activation of Rho Kinase is necessary for HASMC contraction 
and PI3K inhibition promotes bronchodilation of human small airways, the upstream 
mechanisms driving GPCR-mediated PI3K/ROCK axis activation remain unclear.  Since 
G12 family proteins regulate smooth muscle tone by activating Rho Kinase, we 
hypothesize that Gα12 may regulate HASMC contraction by activation of the PI3K/ROCK 
axis.  We used siRNA and pharmacological tools, as well as HASMCs overexpressing 
p115RhoGEF-RGS proteins that limit M3R-mediated activation of Gα12 in order to 
determine the role in modulating PI3K/ROCK axis activation and HASMC contraction.  
Our data showed that knockdown of the M3R attenuated carbachol-induced activation of 
AKT, MYPT1, and MLC phosphorylation.  We also showed that Gα12 
coimmunoprecipitated with the M3R, and that p115RhoGEF-RGS expression limited 
carbachol-mediated induction of SRE-luciferase reporter.  Gα12 siRNA attenuated 
carbachol-induced activation of AKT, MYPT1, and MLC phosphorylation, and that 
p115RhoGEF-RGS overexpression limited carbachol-induced activation of AKT.  
Furthermore, we demonstrated that siRNA and pharmacological inhibition of RhoA 
blunted carbachol-mediated activation of PI3K, and that RhoA inhibitors induced 
dilation of hPCLS, implicating RhoA as a pivotal mediator of airway tone.  Our data 
demonstrate a novel coupling of the M3R to Gα12 HASMCs and that Gα12 plays a crucial 
role in contraction through RhoA-dependent activation of the PI3K/ROCK axis.  We 
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show that inhibition of RhoA induces bronchodilation in hPCLS, and that targeting Gα12 
signaling may elucidate novel therapeutic targets in asthma. 
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Introduction 
 
Airway Hyperresponsiveness (AHR), a hallmark of asthma, represents 
exaggerated airway narrowing in response to contractile agonists such as 
acetylcholine128,129.  Human airway smooth muscle cells (HASMCs) mediate AHR by 
shortening in response to contractile agonists130.  Additionally, HASMCs is the primary 
target of bronchodilators, a cornerstone in the management of asthma39. 
Acetylcholine release from postganglionic parasympathetic nerves innervating 
the airway activates the M3-muscarinic acetylcholine receptor (M3R), a G protein-
coupled receptor expressed by HASMCs 131.  Stimulation of the M3R evokes Gαq/11-
mediated calcium release from the sarcoplasmic reticulum, inducing in MLC Kinase 
(MLCK) activation and myosin light chain (MLC) phosphorylation.  MLC 
phosphorylation induces actomyosin cross-bridge cycling and HASMC shortening132.  In 
parallel, activation of Rho Kinase (ROCK) by the small GTPase RhoA, phosphorylates 
and inactivates MLC Phosphatase (MLCP).  Inhibition of the constitutively active MLCP 
de-phosphorylates MLC, that sustains MLC activation and modulates HASMC tone133,134.   
We recently demonstrated that phosphoinositide 3-kinase (PI3K), a lipid kinase, 
is a necessary mediator of muscarinic receptor-induced ROCK activation and human 
airway bronchoconstriction, and that PI3K inhibitors can reverse carbachol-induced 
bronchoconstriction by attenuating PI3K/ROCK-axis activation43.  The therapeutic 
importance of ROCK signaling is emphasized by the ability of ROCK and PI3K inhibitors 
promote bronchodilation.  The upstream mechanisms regulating muscarinic receptor-
induced ROCK and PI3K activation in HASMC remain unclear and may provide insight 
into novel targets for asthma therapy135. 
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Gα12/13 family members, including Gα12 and Gα13, promote ROCK signaling by 
activating Rho Guanine Nucleotide Exchange Factors (RhoGEFs) including 
p115RhoGEF, that exchange GDP for GTP and activate RhoA136.  p115RhoGEF contains a 
Regulator of G Protein Signaling (RGS) domain, that specifically limits Gα12/13 signaling 
after activation137.  Gα12/13 proteins mediate various cell functions including stress fiber 
formation, cytoskeletal rearrangement, and proliferation138,139.  In the context of HASMC 
function, however, Gα12/13 signaling remains poorly understood.  In rodents, Gα12/13 
proteins contribute to AHR and have elevated expression upon allergen challenge140,141.  
HASMCs express multiple GPCRs that are known to couple to Gα12/13 proteins, including 
PAR, thromboxane, and EDG receptors139.  The M3R has also been shown to couple to 
Gα12/13 proteins in HEK293 cells142 but no studies in HASMCs have confirmed Gα12/13 
coupling to the M3R.  Challenges in employing molecular approaches in primary cells, as 
well as the lack of pharmacological inhibitors against Gα12/13 proteins, provide obstacles 
in characterizing the role of Gα12/13 proteins in HASMC143.   
In this study, we sought to determine the contribution of Gα12/13 proteins in 
muscarinic receptor-induced PI3K/ROCK axis activation in HASMCs.  To study the 
contribution of Gα12/13 proteins in muscarinic receptor signaling, we used siRNA 
transfection in primary HASMCs and newly developed inhibitors that are highly specific 
to RhoA144.  Additionally, we generated HASMC cell lines that overexpress the RGS 
domain of p115RhoGEF, effectively limiting Gα12/13 signaling.  Our data show that Gα12 
couples to the M3R in HASMCs, and that Gα12 plays an important role in facilitating 
HASMC shortening by promoting PI3K-mediated activation of ROCK in a RhoA-
dependent manner. 
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Methods 
 
Materials 
CHRM2 (L-005463-01-0005), CHRM3 (L-005464-00-0005), NT siRNA (D-
001810-10-05), GNA12 (L-008435-00-0005), GNA13 (L-009948-00-0005), RhoA (L-
003860-00-0005), and Rac1 (L-003560-00-0005) siRNA were obtained from 
Dharmacon (Lafayette, CO, USA).  Carbachol (carbamoyl choline chloride), formoterol 
(formoterol fumarate dihydrate), isoprenaline (ISO – isoproterenol hydrochloride), 
bradykinin (bradykinin acetate salt), pertussis toxin and perchloric acid were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  Rhosin (555460) was purchased from EMD 
Millipore (Darmstadt, Germany). Antibodies for detection of pMYPT1-Thr696 (5163S), 
pAkt (4060S), pMLC (3674S) and GAPDH (2118S), total AKT (4691S) were purchased 
from Cell Signalling Technologies (Danvers, MA, USA).  Antibodies for 
immunoprecipitation and detection of the M3 receptor (SC-9108) and Gα12 (SC-409) 
were obtained from Santa Cruz Biotechnology.  Total MLC antibody (MABT180) was 
obtained from EMD Millipore (Darmstadt, Germany).  Total MYPT1 antibody (612165) 
was obtained from BD Biosciences.   
 
Isolation and Culture of HASMC 
Human lungs were received from the National Disease Research Interchange 
(Philadelphia, PA, USA) and from the International Institute for the Advancement of 
Medicine (Edison, NJ, USA) and HASM cells were derived from the tracheas.  All cell 
lines and tissue are obtained from de-identified donors and does not constitute human 
subject research as described by the Rutgers Institutional Review Board.  Culture of 
HASM cells was conducted as described previously145.  Briefly, cells were cultured in 
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Ham’s F-12 medium supplemented with 100 U mL-1 penicillin, 0.1 mg mL-1, 
streptomycin, 2.5 mg mL-1 amphotericin B and 10% FBS.  Medium was replaced every 
72h.  HASM cells were only used during subculture passages 1-4 due to the strong 
expression of native contractile proteins102.  In pertussis toxin studies, cells were treated 
with 1 µg/ml of pertussis toxin for 18h.  All pharmacologic inhibitors were used with 
DMSO as the vehicle at a final concentration of 0.1% and were used to treat HASMC 30 
min prior to agonist stimulation. 
 
Retroviral Infection 
Stable expression of GFP and p115rhogefRGS-GFP was achieved by retroviral 
infection as described previously 146,147Briefly, retrovirus for the expression of each 
construct was produced by cotransfecting GP2–293 cells with pVSV-G vector (encoding 
the pantropic (VSV-G) envelope protein) and pLPCX-GFP or pLPCX-p115rhogefRGS-
GFP.  Forty-eight hours after transfection, supernatants were harvested and used 
to infect human telomerase reverse transcriptase (hTERT) immortalized airway smooth 
muscle cultures, with effective virus concentrations established by immunoblot analysis. 
Cultures were selected to homogeneity with 1 µg mL-1 puromycin as described 
previously146,147. 
 
Generation of hPCLS and Airway Dilation Assays 
hPCLS were prepared as previously described90.  Briefly, human lungs were 
dissected and filled with 2%(w v-1) low melting point agarose.  After the agarose 
solidified, the lobe was sectioned and 8 mm diameter cores were generated.  Cores 
containing small airways were sliced at a thickness of 350 µM using Precisionary 
Instruments VF300 Vibratome.  They were then collected in supplemented Ham’s F-12 
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medium.  Generated slices came from all areas of the lung and not just one specific area.  
Airways from each core were randomized to the different treatment groups prior to the 
start of the experiment.  Airways were constricted to a dose response of carbachol (10-8-
10-5 M), then dilated to one of the following (10-11-10-4 M): diluent (DMSO), formoterol, 
or rhosin.  DMSO alone did not induce airway dilation at the concentrations tested (data 
not shown). 
 To assess luminal area, lung slices were placed in a 12-well plate in media 
and held in place using a platinum weight with nylon attachments. The airway was 
located using a microscope (Nikon Eclipse; model no. TE2000-U; magnification, ×40) 
connected to a live video feed (Evolution QEi; model no. 32-0074A-130 video recorder). 
Airway luminal area was measured using Image-Pro Plus software (version 6.0; Media 
Cybernetics) and represented in mm290. After functional studies, the area of each airway 
at baseline and at the end of dose the response was calculated using Image-Pro Plus 
software. Maximal airway dilation (Emax), sensitivity of the airways to contractile agonist 
– log of the effective concentration to induce 50% airway dilation (log EC50) and the 
integrated response to dilatory agonist – AUC were calculated from the dose-response 
curves generated.  Airway dilation was calculated as % reversal of maximal 
bronchoconstriction.  
 
Statistical analysis 
The data and statistical analysis comply with the recommendations on 
experimental design and analysis in pharmacology. GraphPad Prism software (La Jolla, 
CA, USA) was used to determine statistical significance evaluated by Student's paired t-
test for two groups or ANOVA for multiple groups. P values of <0.05 were considered 
significant. For lung slice analysis, slices were not compared with themselves for each 
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treatment group, so repeated measures analysis was not used. Data were found to be 
normally distributed, and ANOVAs were used for data analysis, with Bonferroni's post 
test. Unpaired t-tests with Welch's correction were used after ANOVAs had established 
significance to compare each inhibitor with formoterol, and conditions within a given 
inhibitor stimulation (for example, −/+ IL-13 for LY294002-induced airway dilation). 
Results were analysed by two-way repeated measures ANOVA with desensitization 
pretreatment (control or salmeterol) as Factor A and bronchodilator test compound 
(isoprenaline or CAL-101) as Factor B. The data passed the normality, and equal variance 
tests and significant effects of both factors were detected. Differences were isolated using 
the Bonferroni t-test for all pairwise comparisons. Immunoblot data and single cell 
contractile data were analysed by Student's two-tailed t-tests. SigmaStat (Systat, San 
Jose, CA, USA) and GraphPad Prism programmes were used in statistical analyses.  
 
siRNA transfection 
Ham’s F-12 media, DharmaFECT 1 reagent, and siRNA were combined in a 
microcentrifuge tube according to manufacturer’s protocol and incubated for 20 min.  
HASMCs were trypsinized and trypsin was inactivated with 5% FBS.  Cells were 
centrifuged and resuspended in Ham’s F-12 media.  Cell suspension was added to siRNA 
mixture and incubated for 15 min.  Cell suspension and siRNA mixture was then seeded 
into cell culture plates according to experimental design and incubated for 6h.  After 6h, 
complete cell culture media (described above) was added to the cell culture plate wells in 
a 1:1 ratio and was incubated for 18h.  After 18h, media was changed to complete media.  
Cells were serum-deprived for 24h before collection.  Cells were collected 72h post-
transfection. 
75	  
	  
 
cAMP Assay 
HASMCs were seeded in a 24 well plate until about 80% confluent and serum-
deprived overnight.  Cells were stimulated and lysed using cAMP-Screen System ELISA 
from Applied Biosystems (Bedford, MA, USA).  Experiment was conducted according to 
manufacturer’s protocol. 
 
SRE-Luciferase Assay 
HASMC were seeded and grown to 75% confluence.  Complete medium was 
removed and Cignal Lenti SRE Reporter (CLS-010L-1) was added to cells with 
SureENTRY Transduction reagent (336921) according to manufacturer’s protocol.  After 
24 h, media was changed to complete medium.  After 24 h, media was changed to serum-
free media.  Following 48h incubation in serum-free media, cells were stimulated with 
carbachol for 6h and collected with luciferase lysis buffer (E1483) from Promega 
(Madison, WI, USA). 
 
Immunoblot Analysis 
After transfection with siRNA or incubation with pharmacologic inhibitors, cells 
were stimulated with carbachol (10 µM – 10 min).  Perchloric acid was added to cell 
media to attain a final concentration of 0.1%.  Cells were scraped, collected, and pelleted.  
Pellets were washed once with ice cold PBS.  PBS was aspirated and pellets were 
solubilized in RIPA.  Sample buffer was added and samples were subjected to SDS-PAGE 
and transferred to nitrocellulose membranes, as previously described43,103. 
Phosphorylation of MYPT1, MLC and AKT were assessed, and band densities were 
normalized to GAPDH, total MYPT1, total MLC, or total AKT band density.  
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Co-immunoprecipitation 
After stimulation, HASMCs grown on 10 cm plates were lysed using ice-cold cell 
lysis buffer from Cell Signaling Technology (Danvers, MA, USA) containing 1% Triton X-
100 with Protease and Phosphatase Inhibitors from Thermo Fisher Scientific (Waltham, 
MA, USA).  Lysate was incubated with primary antibody and incubated overnight with 
gentle rocking at 4°C.  Protein A was incubated with lysates with gentle rocking for 3 
hours at 4°C.  Samples were microcentrifuged for 30 seconds at 4°C.  Pellet was washed 
five times with cell lysis buffer.  Pellet was resuspended with SDS sample buffer and 
heated for 10 min at 70°C.  Sample was then loaded onto SDS-PAGE gel and analyzed by 
immunoblot.   
	  
Results 
 
The M3 muscarinic receptor, not the M2 muscarinic receptor, mediates 
carbachol-induced AKT and MLC phosphorylation.  The M2 and M3 muscarinic 
receptor subtypes are expressed in HASMCs131. In order to determine the receptor(s) 
contributing to carbachol-mediated activation of PI3K/ROCK axis, we examined the 
effects of carbachol stimulation (10  µM, 10 min) on AKT (S473) and MLC (S19) 
phosphorylation in primary HASMCs 72 h after transfection with M2R, M3R, or 
scrambled siRNA. M3R siRNA knockdown reduced M3R protein expression (80 ± 
7%)(Figure 1A).  Scrambled siRNA had little effect on any of the proteins examined.  
M3R siRNA attenuated carbachol-induced phosphorylation of AKT (2.55 ± 0.91 fold vs. 
0.63 ± 0.49 fold) and phosphorylation of MLC (1.44 ± 0.08 fold vs. 0.261 ± 0.287 fold) 
compared to scrambled siRNA (Figure 1 B–C).  Surprisingly, M2R siRNA induced AKT 
77	  
	  
phosphorylation (2.5 ± 0.357 fold) in the absence of agonist.  Since the M2R couples 
predominantly to the G protein Gαi, we used pertussis toxin (18 h, 1 µg ml-1) to ADP-
ribosylate Gαi, rendering it inactive, and measured AKT phosphorylation in response to 
carbachol stimulation (10  µM, 10 min).  Incubation with pertussis toxin before carbachol 
stimulation had little effect when compared to vehicle (0.01% DMSO) (Figure 1D).  
Pertussis toxin, however, rescued carbachol-induced attenuation of isoproterenol-
mediated cAMP elevation (306 ± 23 fold without PTX vs. 461.93 ± 37 fold with PTX). 
 
Gα12 couples to the M3R in HASMCs.  Previous reports in HEK293 cells using GTP 
photolabelling and Gα12-specific RGS overexpression demonstrate that Gα12-is coupled to 
the M3R139,142.  To determine whether coupling occurs in HASMCs we used co-
immunoprecipitation techniques to pull down the M3R and Gα12 proteins.  These 
samples were subsequently immunoblotted for the indicated proteins (Figure 2A).  
When the M3R was co-immunoprecipitated and subsequently probed with Gα12 
antibody, a strong band was present for Gα12.  Upon carbachol stimulation (10  µM, 1 
min), the band density decreased.  Interestingly, when Gα12 was immunoprecipitated 
and subsequently immunoblotted using the M3R antibody, a strong band was also 
present.  Again, band density was decreased upon carbachol stimulation.  To further 
evaluate M3R-Gα12 coupling, hTERT-immortalized HASMCs overexpressing a GFP-
tagged RGS domain of the p115RhoGEF enzyme (p115RhoGEF-RGS-GFP) and 
corresponding control cell lines were infected with an SRE-luciferase reporter construct 
that induces luciferase expression upon Gα12 activation (Figure 2B).  These cells were 
stimulated with carbachol (10  µM, 6 h), lysed, and assayed for luciferase induction using 
luminescence.  Carbachol stimulation elevated luciferase expression (76 ± 18% fold).  
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Carbachol-induced luciferase induction was attenuated to basal levels in HASMCs 
expressing p115RhoGEF-RGS (76 ± 18 fold vs. 1.03 ± 0.3 fold with PTX).   
 
Gα12 mediates M3R-induced activation of PI3K/ROCK axis activation.  To 
determine the contribution of Gα12 proteins to carbachol-induced PI3K/ROCK axis 
activation, we used siRNA to knockdown Gα12 proteins and measured the effects on 
carbachol-induced phosphorylation of AKT, MYPT1, and MLC.  To determine the 
contribution of Gα12 proteins to carbachol-mediated activation of PI3K/ROCK axis, we 
next examined the effects of carbachol stimulation (10  µM, 10 min) on AKT (S473), 
MYPT1 (T696), and MLC (S19) phosphorylation in primary HASMCs 72 h after 
transfection with Gα12 proteins or scrambled siRNA.  Gα12 siRNA knockdown reduced 
Gα12 protein expression (73 ± 9%)(Figure 3A) and scrambled siRNA had little effect on 
any of the proteins examined.  Gα12 siRNA markedly attenuated carbachol-induced 
phosphorylation of AKT (2.55 ± 0.91 fold vs 1.05 ± 0.54 fold), phosphorylation of MYPT1 
(2.1 ± 1.01 fold vs 0.33 ± 0.13 fold), and phosphorylation of MLC (1.44 ± 0.08 fold vs 
0.50 ± 0.39 fold) compared to scrambled siRNA (Figure 3B).  To complement the Gα12 
siRNA studies, we compared carbachol-induced AKT phosphorylation in hTERT-
immortalized HASMC that do/do not express p115RhoGEF-RGS.  In p115RhoGEF-RGS-
expressing HASMCs, carbachol-induced AKT phosphorylation was attenuated compared 
to control cell lines (2 ± 0.52 fold vs. 4.47 ± 1.5 fold) (Figure 3C).  p115RhoGEF-RGS 
expression had little effect on Gαq activation, measured by intracellular calcium 
mobilization (Figure 3D). 
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Gα12-mediated activation of PI3K is RhoA-dependent.  In order to determine 
whether Gα12-mediated activation of PI3K involved Rho and Rac small GTPases as 
signaling intermediates, we examined the effects of carbachol stimulation (10  µM, 10 
min) on AKT (S473) phosphorylation in primary HASMCs 72 h after transfection with 
RhoA, Rac1 or scrambled siRNA.  RhoA and Rac1 siRNA knockdown reduced protein 
expression (68 ± 19% and 66 ± 16% respectively)(Figure 4A) and scrambled siRNA had 
little effect on any of the proteins examined.  RhoA siRNA attenuated carbachol-induced 
phosphorylation of AKT (1.98 ± 0.44 fold vs. 0.71 ± 0.13 fold) compared to scrambled 
siRNA (Figure 4B).  To complement siRNA studies, we next used rhosin to inhibit 
RhoGEFs that activate RhoA and measured AKT phosphorylation in response to 
carbachol stimulation.  Incubation with Rhosin attenuated carbachol-induced 
phosphorylation of AKT (4.4 ± 0.78 fold vs. 0.65 ± 0.09 fold) compared to vehicle 
(Figure 4C).   
 
RhoA inhibition promotes bronchodilation of hPCLS.  To determine if inhibition 
of RhoA reverses agonist-induced bronchoconstriction in human small airways (hPCLS).  
hPCLS were stimulated with carbachol to induce luminal narrowing and subsequently 
treated with increasing doses of Rhosin or Formoterol to evaluate airway dilation (Figure 
5).  Rhosin and formoterol reversed carbachol-induced bronchoconstriction with an 
Emax of 80 ± 5% respectively, as well 100 ± 3% and logEC50 of 1.65e21 and 4.92e7.  
Discussion 
 
Our study demonstrates a previously unidentified role for Gα12 in modulating 
M3R-mediated activation of the PI3K/ROCK axis in HASMCs.  We also demonstrate that 
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Gα12–mediated activation of PI3K/ROCK axis is RhoA-dependent.  Furthermore, we 
show that inhibition of RhoA blunts carbachol-induced PI3K activation and promotes 
bronchodilation of human small airways, implicating RhoA as a pivotal mediator of 
airway tone. 
 To expand on our previous studies demonstrating that PI3K inhibitors promote 
bronchodilation of human small airways, we sought to delineate upstream signaling 
pathways that mediate PI3K activation.   We used siRNA and pharmacological tools, as 
well as HASMCs overexpressing p115RhoGEF-RGS proteins that limit M3R-mediated 
activation of Gα12 in order to determine the role in modulating PI3K/ROCK axis 
activation and HASMC contraction.  Our data showed that knockdown of the M3R 
attenuated carbachol-induced activation of AKT, MYPT1, and MLC phosphorylation.  We 
also showed that Gα12 coimmunoprecipitated with the M3R, and that p115RhoGEF-RGS 
expression limited carbachol-mediated induction of SRE-luciferase reporter.  Gα12 siRNA 
attenuated carbachol-induced activation of AKT, MYPT1, and MLC phosphorylation, and 
that p115RhoGEF-RGS overexpression limited carbachol-induced activation of AKT.  
Furthermore, we demonstrated that siRNA and pharmacological inhibition of RhoA 
blunted carbachol-mediated activation of PI3K, and that RhoA inhibitors induced 
dilation of hPCLS, implicating RhoA as a pivotal mediator of airway tone. 
 Despite its lower expression levels, investigators suggest that the Gαq-coupled M3 
muscarinic receptor, and not the Gαi–coupled M2 muscarinic receptor, is the primary 
subtype responsible for bronchial and tracheal smooth muscle contraction148–152.  
Nonetheless, some studies suggest a role for the M2R in mediating airway smooth 
muscle contraction in the peripheral airways153,154.   Our findings using siRNA against the 
M2R and M3R siRNA, as well as pertussis toxin to inactivate M2R-coupled Gαi 
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demonstrate that the M3R is the dominant receptor mediating the activation of the 
PI3K/ROCK axis (Figure 1).  Incubation with M2R siRNA surprisingly resulted in a 
robust activation of PI3K that possibly could be related to compensatory expression of 
proteins that activate PI3K148.  Our data stand in contrast with studies conducted in 
rabbit intestinal smooth muscle, where the M2R through Gβγ-dependent signaling, 
activates PI3K148.  Interestingly, these cells expressed p110γ isoform of PI3K, that is not 
expressed in the HASMCs used in our studies43,46,52,112.  Gβγ proteins are typically 
thought to signal to the p110γ isoforms of PI3K, not the p110α, p110β, or p110δ isoforms 
expressed in our HASMCs155.  This illustrates an important concept that the identical 
receptors mediate signaling that is tissue and species specific.   
 GPCR-mediated activation of PI3K can occur through epidermal growth factor 
receptor (EGFR) transactivation156.  Previous studies, however, have demonstrated a lack 
of EGFR phosphorylation induced by carbachol in HASMCs157.  Additionally, our data 
demonstrated that EGFR inhibition by tyrphostin had little effect on carbachol-mediated 
AKT phosphorylation, suggesting that EGFR transactivation mediated by the M3R was 
unlikely (Supplemental Figure 1).  Our next goal was to determine which G-proteins 
mediate M3R-induced activation of PI3K.  Since Gβγ proteins were unlikely to mediate 
these signals due to the lack of p110γ expression, we tested whether Gαq mediated these 
signals using a pharmacologic inhibitor FR900359 (UBO-QIC) shown by us and others 
to specifically inhibit Gαq and not other G-proteins or arrestins158,159.  These results 
demonstrated that M3R-induced activation of PI3K was Gαq–independent 
(Supplemental Figure 2).  
Since Gα12/13 family proteins were shown to modulate RhoA/ROCK pathways, we 
used co-immunoprecipitation and SRE-luciferase reporter expressing HASMCs to 
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demonstrate whether M3R coupled to Gα12 in HASMCs (Figure 2).  Our results suggest 
that the M3R indeed is coupled to Gα12 in HASMCs and that M3R-induced activation of 
Gα12 is attenuated by overexpression of the p115RhoGEF-RGS domain.  Furthermore, 
Gα12 siRNA attenuated carbachol-induced AKT, MYPT1, and MLC phosphorylation, 
suggesting for the first time that Gα12 regulates PI3K/ROCK axis activation and MLC 
phosphorylation in HASMCs.  These data agrees with previous studies demonstrating 
M3R-Gα12 coupling in HEK293 cells142.  Other studies have shown a lack of M3R-Gα12 
coupling in murine airway smooth muscle; however, this may be a result of species 
differences between mice and humans.  Our data highlight the importance and necessity 
of Gα12 proteins in maintaining HASMC tone through pathways involving the PI3K-
ROCK axis. 
In order to determine whether Gα12-mediated activation of the PI3K-ROCK axis 
involved RhoA, the canonical effector of Gα12/13 signaling pathways, we used RhoA siRNA 
and Rhosin, a novel rationally design inhibitor of RhoA, to test whether limiting RhoA 
signaling would attenuate PI3K activation.  Our data show that RhoA siRNA and 
inhibitors attenuated carbachol-induced AKT phosphorylation, suggesting PI3K as a 
novel intermediate in Gα12 signaling.  One study has suggested that Rho family GTPases 
and PI3K function cooperatively, offering an explanation for their relationship in Gα12 
signaling160.  Further studies are warranted to study cooperatively in HASMCs.  A 
limitation of our data is that the moderate potency of Rhosin allows the potential for off 
target effects at higher required concentrations.  Our RhoA siRNA data, however, 
support the idea that Gα12-mediated activation of PI3K is RhoA-dependent. 
We demonstrated using hPCLS that RhoA inhibition by rhosin induced 
bronchodilation comparable to formoterol, an industry standard bronchodilator, 
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suggesting that inhibition of our newly established Gα12-mediated signaling pathway 
provides a novel therapeutic strategy for bronchodilation in asthma.   
Our current study and other studies show multiple signaling pathways, kinases, 
and scaffold proteins regulating ROCK activation in HASMCs including those mediated 
by arrestins, Src-family kinases, Gα12, and PI3K43,161–163.  The multiple intermediates 
required for ROCK activation suggest the existence of signaling complexes driving ROCK 
activation.  These complexes are composed of multiple kinases and scaffold proteins, and 
warrant further investigation for several reasons.  Their complexity and arrangement is 
highly cell and tissue specific.  Targeting individual signaling intermediates such as 
kinases has limitations since they are often ubiquitously expressed, allowing for toxicities 
and side effects, even with inhaled delivery systems.  Targeting signaling complex 
formation would provide greater tissue specificity for therapeutics.  Furthermore, using 
combinations of therapeutics to target constituents of ROCK signaling complexes allows 
the potential for combination therapies with lower doses of each individual drug.  This 
would allow improved efficacy with fewer side effects, and could provide for improved 
bronchodilators.  
Our data demonstrate a novel coupling of the M3R to Gα12 HASMCs and that Gα12 
plays a crucial role in contraction through RhoA-dependent activation of the 
PI3K/ROCK axis.  We show that inhibition of RhoA induces bronchodilation in hPCLS, 
and that targeting Gα12 signaling may elucidate novel therapeutic targets in asthma. 
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Figure Legends 
 
Figure 1.  Effects of M2R siRNA, M3R siRNA, and pertussis toxin on 
carbachol-induced AKT and MLC phosphorylation in primary HASMCs.  (A-
C) Measurement of phosphorylation responses to carbachol (10  µM, 10 min) and protein 
expression in primary HASMCs after transfection with M2R, M3R, or scrambled siRNA 
(50 nM, 72 h post-transfection).  (A) Effect of scrambled, M2R and M3R siRNA on 
protein expression.  Data normalized to GAPDH expression in the same samples.  (B) 
Effect of carbachol on AKT phosphorylation at S473 (pAKT) after transfection with 
scrambled, M2R, or M3R siRNA.  pAKT data were normalized to total AKT (AKT).  (C) 
Effect of carbachol on MLC phosphorylation at S19 (pMLC) after transfection with 
scrambled, M2R, or M3R siRNA. pMLC data were normalized to total MLC (MLC).  (D) 
Effect of pertussis toxin (18 h, 1 µg ml-1) on carbachol-induced AKT phosphorylation. 
Data normalized to Tubulin expression in the same samples.  (E) Effect of pertussis toxin 
(18 h, 1 µg ml-1) on carbachol-induced attenuation of isoproterenol-mediated cAMP 
production. Data are expressed as fold change over untreated (basal) samples that were 
measured on the same gel or plate.  Data are representative of five independent 
experiments (n = 5, mean ± SD); statistical comparisons analyzed by unpaired t-test are 
denoted by lines between tested conditions *P < 0.05.  
 
Figure 2.  Gα12 and M3R coupling in HASMCs.  Evaluation of M3R-Gα12 coupling 
using co-immunoprecipitation in primary HASMCs and SRE-luciferase reporter in 
hTERT-immortalized HASMCs expressing p115RhoGEF-RGS.  (A) HASMCs were 
stimulated with carbachol (10  µM, 1 min) and lysates were immunoprecipitated with 
anti-M3R or anti-Gα12 antibody and then probed as indicated.  Immunoblot is 
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representative of five independent experiments.  (B) hTERT-immortalized HASMCs 
expressing p115RhoGEF-RGS and control hTERT-immortalized HASMCs were infected 
with SRE-luciferase reporter.  After carbachol stimulation (10  µM, 6 h), cells were lysed 
and SRE-luciferase reporter activity was measured. Data are expressed as fold change 
over untreated (basal) samples that were measured on the same plate.  Data are 
representative of six independent experiments (n = 6, mean ± SD); statistical 
comparisons analyzed by unpaired t-test are denoted by lines between tested conditions 
*P < 0.05.  
 
Figure 3.  Effects of Gα12 siRNA and p115RhoGEF-RGS overexpression on 
M3R-mediated activation of the PI3K/ROCK/MLC axis in HASMCs.  (A-C) 
Measurement of phosphorylation responses to carbachol (10  µM, 10 min) and protein 
expression in primary HASMCs after transfection with Gα12 or scrambled siRNA (50 nM, 
72 h post-transfection).  (A) Effect of Gα12 or scrambled siRNA on protein expression.  
Data normalized to Tubulin expression in the same samples.  (B) Effect of carbachol on 
AKT, MYPT1, and MLC phosphorylation at S473 (pAKT), T696 (pMYPT1), and S19 
(pMLC) after transfection with Gα12 or scrambled siRNA.  pAKT, pMYPT1, and pMLC 
data were normalized to total AKT (AKT), total MYPT1 (MYPT1), and total MLC (MLC).  
(C) Effect of p115RhoGEF-RGS overexpression on carbachol-induced AKT 
phosphorylation in hTERT-immortalized HASMCs.  (D) Effect of p115RhoGEF-RGS 
overexpression on carbachol-induced intracellular calcium mobilization in hTERT-
immortalized HASMCs.  Data are expressed as fold change over untreated (basal) 
samples that were measured on the same gel or plate.  Data are representative of five 
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independent experiments (n = 5, mean ± SD); statistical comparisons analyzed by 
unpaired t-test are denoted by lines between tested conditions *P < 0.05.  
 
Figure 4.  Effects of RhoA inhibitors and siRNA on M3R-mediated activation 
of PI3K in primary HASMCs.  Measurement of phosphorylation responses to 
carbachol (10  µM, 10 min) and protein expression in primary HASMCs after transfection 
with RhoA, Rac1, or scrambled siRNA (50 nM, 72 h post-transfection) or after incubation 
with Rhosin (RhoA inhibitor) (10  µM, 30 min).  (A) Effect of rhosin on carbachol-
induced AKT phosphorylation at S473 (pAKT).  (B) Effect of scrambled, RhoA and Rac1 
siRNA on protein expression.  Data normalized to MLC expression in the same samples.  
(C) Effect of carbachol on AKT phosphorylation at S473 (pAKT) after transfection with 
RhoA, Rac1, or scrambled siRNA.  pAKT data were normalized to total AKT (AKT).    
Data are expressed as fold change over untreated (basal) samples that were measured on 
the same gel.  Data are representative of five independent experiments (n = 5, mean ± 
SD); statistical comparisons analyzed by unpaired t-test are denoted by lines between 
tested conditions *P < 0.05.  
 
Figure 5.  Effects of RhoA inhibitors on bronchodilation of hPCLS.  
Measurement of bronchodilation responses to rhosin in hPCLS.  Airways were 
preconstricted to carbachol (10−8–10−4 M) prior to dilation to rhosin or formoterol 
(10−10–10−4 M). Data were normalized to maximum forskolin response (10  µM) that was 
given after max dose of formoterol or rhosin. (Maximal airway dilation (Emax, 
ANOVA, P = 0.03) and AUC (P = 0.004) for rhosin was significantly different than 
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formoterol-induced dilation. Data are representative of 6 slices per condition, with bars 
representing mean ± SD. 
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Figure 1 (cont.)	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Figure 1 (cont.)	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Figure 1 (cont.)	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Figure 1 (cont.)	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Figure 2	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Figure 2 (cont.) 
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Figure 3  
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Figure 3 (cont.) 
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Figure 3 (cont.) 
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Figure 3 (cont.) 
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Figure 4 
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Figure 4 (cont.)	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Figure 4 (cont.)	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Figure 5 
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Supplemental Figure Legends 
 
Supplemental Figure 1.  Effect of EGFR inhibition on carbachol-induced 
AKT phosphorylation.  EGFR inhibition by tyrphostin (1 µM) inhibited EGF-induced 
(1 ng/ml) AKT phosphorylation but had little effect on carbachol-induced (10 µM), AKT 
phosphorylation in HASMC. 
 
Supplemental Figure 2.  Effect of Gαq inhibition on carbachol-induced AKT 
phosphorylation.  Gαq inhibition by FR900359 has little effect on carbachol-induced 
(10 µM), AKT phosphorylation in HASMC. 
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Supplemental Figures 
 
Supplemental Figure 1 
pAKT 
D
M
SO
 
                          EGF 
10
-7
 M
 T
yr
ph
os
tin
 
10
-6
 M
 T
yr
ph
os
tin
 
D
M
SO
 
10
-7
 M
 T
yr
ph
os
tin
 
10
-6
 M
 T
yr
ph
os
tin
 
D
M
SO
 
10
-7
 M
 T
yr
ph
os
tin
 
10
-6
 M
 T
yr
ph
os
tin
 
GAPDH 
             Carbachol 
 
 
 
 
 
 
 
 
 
 
 
 
105	  
	  
 
Supplemental Figure 2 
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CHAPTER 4:  Discussion 
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Phosphoinositide 3-kinase inhibitors:  novel bronchodilators 
	  
Asthma management has historically focused on: 1) using bronchodilators that 
bind G protein-coupled receptors (GPCRs) to directly inhibit airway smooth muscle 
(ASM) shortening, prevent (bronchoprotect) or reverse bronchoconstriction 
(bronchodilate); and 2) controlling airway inflammation to limit mediators that induce 
ASM contraction or other structural changes that impede airflow (mucus secretion, 
airway edema).  β-2 agonists, the industry standard bronchodilator, bind to the β-2 
adrenergic receptor on airway smooth muscle (ASM) and inducing Gαs-mediated cAMP 
elevation and protein kinase A (PKA) activation.  PKA will then limit signaling pathways 
that induce ASM shortening such as intracellular calcium mobilization, rho kinase 
(ROCK) activation, and myosin light chain kinase (MLCK) activation.  Unfortunately, 
about 55% of asthmatics have suboptimal control of their symptoms164.   
Despite β-2 agonists’ ability to prevent and mitigate asthma exacerbations, they 
have limitations especially concerning efficacy and safety.  Studies have shown that β-2 
agonist use can result in adverse patient outcomes, β-2 adrenergic receptor 
tachyphylaxis, deterioration of asthma control, and death165,6,5.  New therapeutics are 
needed to overcome these limitations.  New formulations of β-2 agonists offer improved 
specificity and duration of action.  Unfortunately, truly novel therapeutics that overcome 
the limitations of existing drugs have yet to emerge.     
Basic science has identified several novel targets for bronchodilation but none of 
these strategies have translated successfully into clinical utility.  Receptor antagonists 
that block bronchoconstricting agonists include antagonists to the muscarinic, 
histamine, and leukotriene receptors to prevent shortening of ASM135.  Due to the 
multitude of bronchoconstricting mediators present in asthma pathology, however, none 
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have been uniformly effective.  Several alternative Gαs-coupled receptors have been 
discovered including bitter taste receptors, the pH sensing receptor OGR1, and 
prostaglandin-binding EP receptors135.  Regrettably, these receptors lack potent and 
specific ligands, and have similar limitations regarding receptor tachphylaxis. 
 ROCK inhibitors have generated much excitement in the field81.  Since ROCK 
activation is necessary to maintain ASM tone by inhibiting MLC phosphatase, ROCK 
inhibitors allow the constitutively active MLC phosphatase to de-phosphorylate MLC 
and allow relaxation of ASM.  ROCK inhibitors blunt ASM contraction and induce 
bronchodilation in vitro, ex vivo, and in vivo166,167,106,168–170.  The limitation with targeting 
ROCK is that it is ubiquitously expressed, making the potential for undesired side effects 
high.  Studies have shown that ROCK can induce hypotension as a result of 
vasodilation171.  Despite the plethora of promising findings from animal studies that 
demonstrate effective bronchodilation, clinical trials in humans have not been published.  
Inhibiting ROCK is an effective approach to induce bronchodilation, but strategies need 
to be developed to avoid off target effects.  These strategies can include improved 
targeting to airway smooth muscle, or elucidating the signaling pathways that drive 
ROCK activation in order to identify novel mediators that are not expressed in all smooth 
muscle cells. 
    We present a novel strategy to induce bronchodilation in human airways by 
inhibiting the p110δ isoform of phosphoinositide 3-kinase (PI3Kδ)43.  In primary human 
ASM cells (HASMCs), we demonstrated that PI3Kδ modulates ROCK activation, and that 
inhibition of PI3Kδ using a FDA approved drug Cal101 (Idelalisib) attenuates ROCK 
activation.  Cal101 induced relaxation of cultured HASMCs by inhibiting PI3Kδ-mediated 
activation of ROCK.  Using human precision-cut lung slices, we also demonstrated that 
Cal101 induces bronchodilation of human small airways as effectively as formoterol, an 
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industry standard β-2 agonist.  Cal101 displayed similar potency to Y27632, a ROCK 
inhibitor.  In the context of β-2 agonist tachyphylaxis, the effectiveness of β-2 agonists 
were significantly attenuated while the effectiveness of Cal101 was not.  Thus, our results 
suggest that PI3Kδ inhibitors represent a novel class of bronchodilators. 
Advantage and limitations of PI3Kδ inhibitors as asthma therapeutics 
	  
Inhibition of PI3Kδ is an exciting strategy because it can potentially overcome 
limitations of current therapies.  PI3Kδ inhibitors are small molecules that can bypass 
cell surface receptors and bind to their intracellular target.  By bypassing receptors, 
PI3Kδ inhibitors overcomes tachyphylaxis due to receptor desensitization and 
internalization.  Furthermore, PI3Kδ inhibitors can reverse β-2 receptor desensitization 
and tachyphylaxis to a degree172.  Since PI3Kδ inhibitors can reverse airways pre-
constricted to multiple agonists, these inhibitors potentially can be effective in the 
presence of the multiple mediators present in the airway during asthma exacerbations, 
unlike cell surface receptor antagonists.  PI3Kδ exhibits tissue-selective expression and is 
not expressed ubiquitously like PI3Kα/PI3Kβ isoforms and ROCK173 (Table 1.1). Our 
studies provide a rationale for PI3Kδ inhibitors to have the potential for a better 
therapeutic window, especially with inhaled delivery systems.   
 In the context of asthma, PI3Kδ inhibitors have been extensively studied due to 
their anti-inflammatory properties173.  Studies showed these inhibitors are effective anti-
inflammatory agents despite corticosteroid insensitivity.  As a result of many successful 
studies, PI3Kδ inhibitors have been moving through clinical trials for asthma steadily.  
GSK2269557, RV1729, and IPI-145 have progressed into Phase 2 clinical trials as inhaled 
formulations (Table 2.1).  Furthermore, Idelalisib was FDA approved in 2014 for 
indolent non-Hodgkin’s lymphoma83.  The success of PI3Kδ inhibitors in clinical trials 
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makes the potential for PI3Kδ inhibitors to translate into the clinic as bronchodilators 
more likely than other potential candidates.  The capability to function as a 
bronchodilator and as an anti-inflammatory provides evidence to suggest that PI3Kδ 
inhibitors may complement β-2 agonist and corticosteroids in the treatment of asthma. 
 Like all therapeutic agents, challenges exist with PI3Kδ inhibitors.  Kinase 
inhibitors have limitations including specificity and adverse effects, due in part to off-
target effects and loss of efficacy over time.  Kinase inhibitors usually target the ATP-
binding pocket and since ATP is present in high concentrations, kinase inhibitors 
typically require nanomolar potency to be effective.  Unfortunately, targeting the ATP-
binding pocket attenuates specificity and evokes greater potential for off-target effects.  
Recent studies suggest that kinase inhibitors with high specificity can be developed 
based on an understanding of the cocrystal structure of the ATP-ligand binding site of 
kinases174.  Additionally, approaches targeting allosteric sites that are distant from the 
ATP-binding sites have been successful with over 10 allosteric kinase inhibitors now in 
clinical development175.  Further, we can mitigate off-target effects for airway disease 
with topical delivery systems such as inhalers.  These systems deliver drugs directly into 
the airway, limiting systemic side effects. 
Molecular mechanisms of GPCR-mediated PI3K and ROCK activation 
	  
GPCR-mediated regulation of ROCK is complex.  Upstream elements are 
recruited to activate ROCK in HASMC.  Some examples include G proteins, arrestins, 
and src family kinases.  Elucidating these upstream elements become especially 
important in airway biology because disruption of their action serves as potential 
therapeutic strategies.  To delineate the upstream signaling pathways involved in the 
regulation of PI3K and ROCK, we systematically tested the signaling elements proximal 
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to the pro-contractile muscarinic acetylcholine receptor 3 (M3R) that mediate activation 
of PI3K and ROCK.  We used siRNA and pharmacologic inhibitors in hPCLS and primary 
HASMCs including expression of p115RhoGEF-RGS domain proteins that limit Gα12 
signaling.  For the first time, we demonstrate that the M3R does couple to Gα12 in 
HASMCs.  We have demonstrated that Gα12 is necessary for the activation of the 
PI3K/ROCK axis and that activation is dependent on RhoA (Figure 1).  Finally, we 
demonstrate that inhibitors of RhoA can induce bronchodilation of hPCLS.   
 In airway biology, investigators have focused on understanding how GPCR’s 
mediate ROCK activation.  Recently, several signaling molecules have emerged as 
necessary for GPCR-mediated activation of ROCK including arrestins, src family kinases, 
focal adhesion kinases, G-proteins, and PI3K43,162,163,161.  Interestingly, these molecules 
are necessary but not sufficient for ROCK activation because multiple pathways are 
required for ROCK activation to occur that include scaffolding proteins, as well as 
enzymes such as kinases.  The assembly of signaling scaffolds poses interesting 
therapeutic targets. 
 First, the necessity of multiple kinases for ROCK activation suggests that 
combinations of kinase inhibitors at lower doses to disrupt the signaling cascade at 
multiple nodes can effectively blunt downstream activation of ROCK.  Inhibiting 
multiple kinases may increase efficacy since these agents may be additive or act 
synergistically81.  Additionally, inhibiting multiple kinases decreases the chances of 
developing resistance by blocking pathways that are upregulated in compensatory 
response to mono-kinase inhibition, that occurs with continued use of inhibitors.  As an 
example, several multikinase inhibitors have been developed in inhaled formulations for 
the treatment of steroid-resistant inflammation in severe asthma and COPD81.  These 
drugs inhibit p38α, p38γ, and Hck, and are more effective than p38α inhibitors alone in 
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suppressing the release of inflammatory cytokines from macrophages in vitro and in 
treating inflammation in mice exposed to cigarette smoke. 
 Secondly, the assembly of signaling complexes suggests that we can target 
protein-protein interactions pharmacologically in order to destabilize complex 
formation.  With kinase inhibitors, specificity and design of pharmacologic agents 
remains challenging since there exists limited structural features like the ATP-binding 
that can be targeted pharmacologically.  With signaling complexes, there are more 
structural features that provide targets that offer attractive possibilities for developing 
improved therapeutics.  Since each cell has a unique array of molecules that assemble to 
activate ROCK, targeting multiple kinases and targeting signaling complexes in ASM 
would offer greater specificity and less potential adverse effects.  Coupled with inhaled 
delivery systems, this would suggest powerful new strategies to develop improved 
bronchodilator therapies.  
Future Directions 
	  
To further investigate signaling cascades and signaling complexes, we can employ 
sophisticated mass spectrometry-based proteomics strategies to determine quantitative 
and temporal dynamics of agonist-mediated activation of ROCK176.  Bioinformatics 
software can then interpret this information to generate an unbiased list of 
phosphorylated proteins responding to the stimulus.  This information can be further 
analyzed to determine kinases that are activated upon stimulation.  Kinases with 
available inhibitors or siRNA can then be tested for contribution to ROCK signaling.   
 To determine complex formation, we can use proteomics again but with a 
different experimental design.  We can express ROCK or scaffolding proteins like 
arrestins with a C terminal FLAG tag epitope in HASMCs177f.  Following agonist 
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stimulation, we can immunoprecipitate these proteins and all interacting proteins using 
anti-FLAG antibodies.  These samples can then undergo proteomic analysis to determine 
proteins associated with ROCK or scaffolding proteins like arrestins.  Protein 
interactions can then perturbed using siRNA and inhibitors in order to determine their 
contribution to the formation of ROCK signaling complexes. 
 To extend our discovery that PI3K inhibitors can bronchodilate, we will conduct 
hPCLS experiments testing PI3K inhibitors in combination with β-2 agonists to 
determine if they display additive or synergistic effects.  Studies suggest that muscarinic 
antagonists can act synergistically with β-2 agonists178.  We will investigate whether PI3K 
inhibitors and β-2 agonists act synergistically or additively.  For this experiment, we can 
establish dose response curves for each compound and determine isoeffective 
concentrations.  We will then examine dual drug interactions using isoeffective 
concentrations.  Finally we can use statistical models such as the Bliss Independence 
model to determine whether drugs are additive, synergistic, or antagonistic178. 
 Our observations that Gα12 and Gαq proteins are required to activate RhoA and 
ROCK were surprising.  Gα12 are predominantly coupled to GPCRs that are also coupled 
to Gαq.  Gαq can also activate RhoA and ROCK and begs the question what is the role of 
Gα12?  Interestingly, Gα12 manifests orders of magnitude slower GDP on/off rates than 
other G proteins, suggesting that activation is slower and prolonged136.  Accordingly, I 
posit that cells need Gαq for the initial mobilization of calcium and generation of tone 
and that Gα12 sustains signaling and maintains bronchomotor tone.  This is supported by 
data showing that Cal101 induces bronchodilation when given after bronchoconstricting 
to agonist, but fails to prevent bronchoconstriction when given before agonists and 
suggests that Cal101 has little effect when given before agonist when Gαq is active.  After 
agonist stimulation and attenuation of Gαq activation pathways, however, Cal101 induces 
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bronchodilation by inhibiting pathways activated by Gα1243.  Accordingly, this suggests 
that Gαq inhibition prevents bronchoconstriction when given before 
bronchoconstriction, but should be ineffective in inducing bronchodilation when given 
after agonist since this is when Gα12 signaling dominates158.  We well pursue this 
hypothesis using BRET biosensor assays to determine the temporal aspects of G protein 
signaling in hPCLS experiments162. 
Conclusions 
	  
β-2 agonists are the industry standard bronchodilator for acute rescue therapy 
during asthma exacerbations, as well as controller therapy to prevent asthma symptoms.  
Unfortunately, patients with asthma still suffer from suboptimal control due to 
limitations including safety, efficacy, and tachyphylaxis.  Promising candidates have 
emerged such as ROCK inhibitors.  Due to limitations such as unacceptable adverse 
effects, these inhibitors have unfortunately been unable to progress into clinical trials. 
In this dissertation, we determined that inhibitors of PI3Kδ could function as 
novel bronchodilating agents by blunting signaling that leads to ROCK activation.  PI3Kδ 
inhibitors promote bronchodilation with similar efficacy as β-2 agonists and ROCK 
inhibitors.  PI3Kδ is not ubiquitously expressed like ROCK, and may therefore offer a 
better therapeutic window.  Importantly, we also found that PI3Kδ inhibitors evoke 
bronchodilation in the context of β-2 adrenergic receptor desensitization and 
tachyphylaxis, suggesting that PI3Kδ inhibitors may be promising alternate therapeutics 
when β-2 agonists fail to be effective.  In cancer studies, PI3Kδ inhibitors have been FDA 
approved for non-Hodgkin’s lymphoma and others remain in Phase 2 clinical trials for 
asthma.  Success in clinical trials makes PI3Kδ inhibitors exciting candidates to be 
repurposed for asthma. 
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We have also demonstrated for the first time that Gα12 mediates M3R-induced 
activation of PI3K and subsequently ROCK.  These results reveal a completely novel 
pathway regulating M3R signaling that is necessary to elicit HASMC shortening.  
Importantly, our work has uncovered several new targets for bronchodilation and has 
offered new avenues for translation of science. 
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Figure Legends 
 
Figure 1.  Summary of Gα12-mediated ROCK Signaling in HASMC.  Upon 
stimulation by acetylcholine, the M3 muscarinic acetylcholine receptor activates Gα12, 
resulting in RhoA-mediated activation of PI3K and ROCK. 
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